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PNMT AS A NOVEL MARKER FOR 
PROGENITOR CELLS 
RELATED APPLICATIONS 
This application is a continuation of U.S. Ser. No. 11/918, 
678 filed Nov. 21, 2008 now abandoned which claims priority 
to PCT/US2005/010611 filed Mar. 31, 2005 which claims the 
benefit of the filing dates of U.S. Provisional Application No. 
60/557,785, filed Mar. 31, 2004; U.S. Provisional Application 
No. 60/558,146, filed Apr. 1, 2004; and U.S. Provisional 
Application No. 60/562,931, filed Apr. 16, 2004. The entire 
teachings of the referenced Provisional Applications are 
incorporated herein by reference in their entirety. 
FUNDING 
Work described herein was funded, in whole or in part, by 
funds from the National Institute of Child Health Develop-
ment (NICHD). The United States government has certain 
rights in the invention. 
SEQUENCE LISTING 
The instant application contains a Sequence Listing which 
has been submitted in ASCII format via EFS-Web and is 
hereby incorporated by reference in its entirety. Said ASCII 
copy, created on Nov. 22, 2011, is named 1669107C.txt and is 
1,126 bytes in size. 
FUNDING 
Work described herein was funded, in whole or in part, by 
funds from the National Institute of Child Health and Human 
Development (NICHD). The United States government has 
certain rights in the invention. 
BACKGROUND OF THE INVENTION 
2 
(e.g., embryonic) or adult tissue/organs. In certain cases, the 
subject progenitor cells differentiate into adrenergic cells. In 
certain other cases, the Pnmt-positive progenitor cells tran-
siently differentiate into adrenergic-like cells, followed by 
further differentiation into cardiomyocytes, neuronal, and/or 
other specialized cell types. 
In one specific embodiment, the Pnmt-positive progenitor 
cell is a cardiac progenitor cell (also referred to as cardiomyo-
cyte progenitor cell). The Pnmt-positive cardiac progenitor 
10 cell may be also positive for other markers, such as c-kit, 
Sca-1, and MDRl. In certain embodiments, the progenitor 
cells differentiate into a cardiomyocyte in vivo, in vitro or ex 
vivo. Examples of cardiomyocytes include, but are not lim-
15 ited to, a pacemaker cell, such as a sinoatrial node (SAN) cell 
or an atrioventricular node (AYN) cell; a His bundle (HIS) 
cell; a Purkinje fiber (PUR) cell; an atrial working myocyte; 
and a ventricular working myocyte. The Pnmt-positive pro-
genitor cell can be isolated, for example, from stem cell 
20 cultures or from developing hearts or adult hearts. 
In another specific embodiment, the Pnmt-positive pro-
genitor cell is a neural progenitor cell. The Pnmt-positive 
neural progenitor cell may also be positive for other markers, 
such as nestin. In certain embodiments, the progenitor cells 
25 differentiate into a neuronal cell, such as a brainstem neuronal 
cell or a retinal neuronal cell. This Pnmt-positive progenitor 
cell can be isolated, for example, from stem cell cultures or 
from developing brains or adult brains. 
In certain embodiments, the present invention provides a 
30 method for identifying a cardiac progenitor cell. In this 
method, Pnmt expression is detected within a cell. If the cell 
expresses Pnmt and differentiates into a cardiomyocyte, then 
the cell is identified as a cardiac progenitor cell. Examples of 
cardiomyocytes include, but are not limited to, a pacemaker 
35 cell, such as a sinoatrial node (SAN) cell or an atrioventricular 
node (AYN) cell; a His bundle (HIS) cell; a Purkinje fiber 
(PUR) cell; an atrial working myocyte; and a ventricular 
working myocyte. The cell may also be positive for other 
markers, such as c-kit, Sca-1, andMDRl. In certain cases, the 
Cure of a wide variety of diseases or tissue injuries by 
specific replacement of damaged or malfunctional tissues by 
use of totipotent, pluripotent or multipotent stem cells is on 
the horizon in clinical practice (see, e.g., Fuchs, et al., 2000, 
Cell, 100:143-156; Weissman et al., 2000, Cell, 100:157-168; 
Blau, et al., 2001, Cell, 105:829-841). To transmute a somatic 
cell into the variety of cell types needed for tissue regenera-
tion and reconstruction in vertebrates is a realistic goal. In 
fact, tissues that were formerly considered incapable of 
extensive regeneration, such as brain, spinal cord, and cardiac 45 
muscle, now appear to be capable of reconstruction function-
ally, at least to some extent, by stem cell populations. Stem 
cells derived from the embryo and from adult tissues have 
been shown to have extensive potentials for self-renewal and 
differentiation. 
40 cell is isolated from stem cell lines/cultures or from a mam-
malian tissue such as a developing or adult heart. In a specific 
embodiment, the cell used in this method comprises a marker 
gene located at one or more loci of the Pnmt gene. Thus, 
expression of the marker gene recapitulates expression of 
Pnmt. Cardiac progenitor cells can then be readily detected by 
fluorescence-activated cell sorting (F ACS), which detects the 
marker expression. Useful markers include, but are not lim-
ited to, beta-galactosidase, luciferase, fluorescent proteins 
such as GFP (green), BFP (blue), RFP (red), YFP (yellow), 
50 CFP (cyan), and other suitable markers (e.g., a cell-surface 
protein such as a membrane receptor). Therefore, there is a need to develop methods of identify-
ing or isolating stem cells for tissue reconstruction proce-
dures. Investigation in these areas may lead to realistic 
approaches in the future for stem cell therapy in a variety of 
human diseases, tissue injuries, and other clinical problems. 
SUMMARY OF THE INVENTION 
In certain embodiments, the present invention provides an 
isolated progenitor cell that expresses phenylethanolamine 
n-methyltransferase (Pnmt), referred to herein as a "Pnmt-
positive" progenitor cell, including a mammalian progenitor 
cell (e.g., human or mouse). The Pnmt-positive progenitor 
cells can be isolated from various pluripotent stem cell cul-
tures (e.g., adult bone marrow-derived stem cells, adipose-
derived stem cells, cardiac-derived stem cells, neural-derived 
stem cells, embryonic stem cells, etc.), or from developing 
In certain embodiments, the present invention provides a 
method of inducing a Pnmt-positive cardiac progenitor cell to 
differentiate into a cardiomyocyte. In this method, the Pnmt-
55 positive cardiac progenitor cell is treated with an effective 
amount of one or more agent that induces the progenitor cell 
to differentiate into a cardiomyocyte. Examples of cardi-
omyocytes include, but are not limited to, a pacemaker cell, 
such as a sinoatrial node (SAN) cell or an atrioventricular 
60 node (AYN) cell; a His bundle (HIS) cell; a Purkinje fiber 
(PUR) cell; an atrial working myocyte; and a ventricular 
working myocyte. The progenitor cell may also be positive 
for other markers, such as c-kit, Sca-1, and MDRl. In certain 
cases, the progenitor cell is isolated from stem cell lines/ 
65 cultures or a mammalian tissue (e.g., human), such as a devel-
oping or adult heart. The agents used this method to induce 
differentiation include, but are not limited to, catecholamines 
US 8,614,091 B2 
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(norepinephrine or epinephrine), growth factors, hormones, 
and extracellular matrix proteins. 
4 
the Pnmt gene is contacted with a test compound. The expres-
sion level of the marker gene in the cell is determined. If the 
expression level of the marker gene is higher in the presence 
of the test compound than in the absence of the test com-
pound, the test compound is a compound that increases 
expression of Pnmt. Optionally, the identified compound can 
also increase the level of epinephrine in a cell. In certain 
cases, the subject method further includes assessing the abil-
ity of the test compound to increase expression of Pnmt in 
In certain embodiments, the present invention provides a 
method of treating a patient having a myocardial injury. In 
this method, at least one (one or more) Pnmt-positive cardiac 
progenitor cell is obtained and transferred into the patient, 
wherein the progenitor cell differentiates into a cardiomyo-
cyte. Typically, cells identified as Pnmt-positive cardiac pro-
genitor cells are cultured under conditions that result in their 
propagation, in order to produce a sufficient number of cells 
for the desired purpose. Examples of cardiomyocytes 
include, but are not limited to, a pacemaker cell, such as a 
sinoatrial node (SAN) cell or an atrioventricular node (AYN) 
cell; a His bundle (HIS) cell; a Purkinje fiber (PUR) cell; an 
atrial working myocyte; and a ventricular working myocyte. 
The progenitor cell may also be positive for other markers, 
such as c-kit, Sca-1, and MD RI. In certain cases, the progeni-
10 vivo (e.g., in an animal). 
In certain embodiments, the present invention provides a 
non-human transgenic animal whose genome comprises a 
marker gene located at one or more loci of the Pnmt gene. 
Optionally, at least one (one or two) copy of the Pnmt gene is 
tor cell is isolated from stem cell lines/cultures or a mamma-
lian tissue (e.g., human), such as a developing or adult heart. 
Specific examples of myocardial injuries include myocardial 
infarction, cardiomyopathy, and congenital heart disease. 
Preferably, the progenitor cell is transferred to a damaged 
cardiac region. 
15 deleted in the animal. Exemplary markers include, but are not 
limited to, beta-galactosidase, luciferase, fluorescent proteins 
such as GFP (green), BFP (blue), RFP (red), YFP (yellow), 
CFP (cyan), and other suitable markers (e.g., a cell-surface 
protein such as a membrane receptor). For example, the trans-
20 genie animal includes mouse, rat, and rabbit. 
In certain embodiments, the present invention relates to use 
of the isolated Pnmt-positive progenitor cells (e.g., cardiac 
progenitor cells) for treating myocardial injury in a patient. 
Specific examples of myocardial injuries include myocardial In a specific embodiment, the subject method further 
includes expanding the Pnmt-positive progenitor cell ex vivo 
before transferring progenitor cells into the patient. 
In another specific embodiment, the subject method further 
includes treating the patient with an immunosuppressive 
agent, such as FK-506, cyclosporin or GAD65 antibodies. In 
certain embodiments, expression of at least one major histo-
compatibility (MHC) gene (e.g., class I MHC, class II MHC, 
or class I and II MHC) is inactivated in the Pnmt-positive 
progenitor cell. 
25 infarction, cardiomyopathy, and congenital heart disease. The 
isolated progenitor cell is optionally transferred to a damaged 
cardiac region. 
In certain embodiments, the present invention provides a 
method of delivering a scaffold graft in a target tissue, com-
In certain embodiments, the present invention provides a 
transplant graft comprising the subject Pnmt-positive pro-
genitor cells. Preferably, the transplant graft does not cause 
graft versus host rejection when transplanted into an animal. 
30 prising: a) seeding Pnmt-positive progenitor cells onto a bio-
compatible scaffold, thereby forming a scaffold graft; and b) 
implanting the scaffold graft from (a) in direct contact with, or 
adjacent to, a target tissue for a sufficient time, wherein cells 
of the target tissue associate with the implanted scaffold graft, 
35 thereby to form new tissue. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIGS. lA-lC show construction and verification of the 
Pnmt-Cre allele. (A) Cartoon depiction of the wild-type and 
Pnmt-Cre alleles. Sequences coding for the Pnmt RNA are 
depicted as an open rectangle with the direction of transcrip-
tion indicated by the arrow. The thickened line shows the 
Pnmt sequences used to direct the homologous recombina-
tion event that introduces the Cre-recombinase gene (Cre) 
and the Neomycin resistance gene (NeoR) into Pnmt exon 1. 
Cre-recombinase is fused to the Pnmt 5' UTR sequences so 
that its transcription is entirely dependent upon Pnmt regula-
tory elements. The Cre insert contains transcriptional stop 
In certain embodiments, the present invention provides a 
method of assessing a Pnmt-positive cardiac progenitor cell 
for its ability to regenerate cardiac tissues in vivo. In this 40 
method, a Pnmt-positive cardiac progenitor cell is obtained 
and transferred into a subject in need thereof. Preferably, the 
transferred progenitor cell contains a marker (e.g., a fluores-
cent marker). Then, the transferred progenitor cell is moni-
tored by methods, for example, magnetic resonance imaging 45 
(MRI) or bioluminescence imaging (BLI). Useful markers 
include, but are not limited to, beta-galactosidase, luciferase, 
fluorescent proteins such as GFP (green), BFP (blue), RFP 
(red), YFP (yellow), CFP (cyan), and other suitable markers 
(e.g., a cell-surface protein such as a membrane receptor). 
In certain embodiments, the present invention is a cell 
comprising a marker gene located at one or more loci of a 
Pnmt gene. Optionally, at least one (one or two) copy of the 
Pnmt gene is deleted in the cell. Useful markers include, but 
are not limited to, beta-galactosidase, luciferase, fluorescent 55 
proteins such as GFP (green), BFP (blue), RFP (red), YFP 
(yellow), CFP (cyan), and other suitable markers (e.g., a 
cell-surface protein such as a membrane receptor). Prefer-
ably, the cell is a mammalian cell (e.g., human). In certain 
cases, the cell is a progenitor cell. 
50 sequences. NeoR is driven by its own promoter and the NeoR 
gene is flanked with Frt sites to allow its removal via Flp 
recombinase. The 5' and 3' probes used for verifying the 
alleles are depicted. (B) Southern analysis of the mutated cell 
lines identifies clones carrying the Pnmt-Cre insertion allele. 
When digested with XbaI and Eco RI, correctly targeted cells 
display an 8 kb band (5' Probe/Left Panel) or a 6 kb band (3' 
probe/Right Panel) in addition to the 14 kb band indicative of 
the wild-type chromosome. (C) PCR analysis described in the 
Methods distinguishes homozygous wild type ( +!+ ), het-
In certain embodiments, the present invention is a method 
of making the subject cell comprising a marker gene located 
60 erozygous mutant ( +/Cre ), and homozygous mutant (Cre/ 
Cre) animals. RI, EcoRI; S, SacI; Xb, Xbal. 
at one or more loci of the Pnmt gene. 
In certain embodiments, the present invention relates to a 
method of identifying a compound that increases expression 65 
of Pnmt in a cell such as a progenitor cell. In this method, a 
cell comprising a marker gene located at one or more loci of 
FIGS. 2A-2F show co-immunofluorescent and XGAL his-
tochemical staining in neonatal adrenal sections in Pnmt-Cre/ 
R26R mice. (A) PNMT immunofluorescent histochemical 
staining (FITC filters). (B) Adjacent section stained with 
XGAL. (C) PNMT immunofluorescent histochemical stain-
ing of the section shown in (B) after X GAL staining. Note that 
US 8,614,091 B2 
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the XGAL staining blocks the fluorescent signal in co-stained 
cells. (D) TH Immunofluorescent histochemical staining 
(Texas Red filter) of the same section as shown in (A). (E) TH 
Immunofluorescent histochemical staining of an adjacent 
section (same section as shown in panels B&C) after XGAL 5 
staining. (F) Overlay ofimages in panels D and E showing TH 
Immunofluorescent and XGAL staining simultaneously. 
Arrows in panels E and F indicate examples of TH+ cells that 
were not stained with XGAL. Scale bar, 0.1 mm. 
FIGS. 3A-3B show whole-mount XGAL staining of an 10 
ES.5 Pnmt-Cre/R26R embryo. (A) Left ventral view. Arrow 
points to Lacz+ blue-stained cells in the sinus venosus (SV) 
region. Arrowheads indicate positions of additional Lacz+ 
cells in this heart. (B) Right dorsal view. Arrows point to 
Lacz+ blue-stained cells along the dorsal crest of the neural 15 
folds (NF). Scale bar, 1.0 mm. 
FIGS. 4A-4B show whole-mount XGAL staining in El 0.5 
mouse embryos. (A) Pnmt-Cre/R26R and (B) Wild-type 
(Pnmt+1+)/R26R mouse embryos at El0.5. Right sagittal 
views are shown. The arrow depicts the heart. Staining can 20 
also be seen in the brainstem and 2nd branchial arch regions. 
Sparse patches ofXGAL staining are also seen along the back 
(dorsal surface) and in the forelimb of the Pnmt-CrexR26R 
embryo. Scale bar, 1.0 mm. 
FIGS. SA-SD show identification of Lacz+ cells in El0.5 25 
mouse heart sections. (A-D) Series of sagittal sections from 
left to right through an El0.5 heart from a Pnmt-Cre/R26R 
embryo that was stained with X GAL and counterstained with 
eosin are shown. Arrows depict areas of the heart that were 
stained blue with XGAL. Abbreviations: Atr, atrial chamber, 30 
AV, antrioventricular; OT, outflow tract SA, sinoatrial; Vent, 
ventricular chamber. Scale bar, 0.1 mm. 
6 
boxed region from panel A. (B) Bright-field image of blue 
XGAL-stained cells in the SAN region. (C) HCN4 immun-
ofluorescent (green) staining of the same section shown in 
panel B. (D) Overlay image of panels B and C. (E) Pnmt 
immunofluorescent (green) staining of an equivalent region 
to that shown in panels B-D from an adjacent section. Scale 
bar, 0.1 mm. Arrowheads point to the equivalent region in 
each panel where Pnmt+ cells were found. Arrows in panels C 
and D indicate examples of pacemaker cells co-stained for 
HCN4 and XGAL. 
FIGS. 9A-9H show co-immunofluorescent histochemical 
staining in sagittal sections from El0.5 Dbh+1- and Dbh-1-
mouse embryos. (A-D) Low-magnification (!Ox objective) 
view of a-actinin and HCN-4 staining in Dbh+1- (A&B) and 
Dbh_;_ (C&D) embryos. The arrow indicates the presumptive 
SA-node region at the mouth of the inlet to the atrial chamber. 
(E-H) High-magnification (60x objective) of the SA-node 
region in an adjacent section co-stained for Cx43 (E&G) and 
HCN-4 (F&H) in Dbh+1- (E&F) and Dbh-1- (G&H) mouse 
embryos. 
FIG. 10 shows ~-adrenergic stimulation of Cx43 expres-
sion in cultured neonatal rat cardiomyocytes. The cultures 
were allowed to develop spontaneous, synchronous beating 
activity for 7 days prior to drug treatment. The indicated drugs 
(10 µMeach) were added to the culture media from a lOOx 
stock, and the cells were returned to the incubator for 5 hrs. 
Protein extracts were prepared, separated by SDS-PAGE, 
electro-transferred to PVDF membrane and reacted with 
either an anti-Cx43 or an anti-a-actinin antibody. The blots 
were developed using chemiluminescence and autoradiogra-
phy. Abbreviations: Con, control (no drugs); Iso, isoproter-
enol; Tim, timolol; Epi, epinephrine; Cx43, connexin 43. 
FI GS. 6A-6D show co-immunofluorescent and X GAL his-
tochemical staining in an E9.5 Pnmt-Cre/R26R mouse heart. 
The same section is shown in panelsA-D (right sagittal view). 
(A) Sarcomeric a-actinin, a myocyte-specific marker, is visu-
alized as Texas Red fluorescent staining. (B) Bright-field 
image depicting Lacz+ cells (stained blue with XGAL). (C) 
Pnmt, an I CA cell marker, is seen as green (FITC) fluorescent 
staining. (D) Overlay image showing all three staining pat-
terns simultaneously. Yellow regions represent apparent co-
staining for sarcomeric a-actinin and Pnmt (arrows). The 
arrowheads depict regions of the embryo that were stained 
exclusively for Pnmt. Scale bar, 0.1 mm. 
FIG. 11 shows comparison of action potentials recorded 
from various regions of embryonic rat hearts at different 
35 stages of prenatal development. Action potentials that were 
recorded in my laboratory are shown outside the boxed region 
of the E12.5 heart diagram. 
FIG. 12 shows an example of optical mapping experiment 
using El0.5 mouse heart. Microarray detection of action 
40 potentials generated from a spontaneous impulse are shown 
on the left, and an expanded view of selected action potentials 
is shown to the right. Time of activation was estimated by 
comparing the half-maximal intensity signal for each action 
potential. 
FIG. 13 is a schematic illustration of cardiomyocyte dif-
ferentiation. This picture represents an overly simplified view 
of how cardiomyocytes may differentiate from embryonic 
stem (ES) cells. Alternatively, "ES cells" could be replaced 
with "fertilized oocyte". The question marks in the block 
FIGS. 7A-7H show Pnmt-Cre expression in the SAN 45 
region of E15.5 mouse hearts. Communofluorescent his-
tochemical staining of wild-type (Pnmt+1+) E15.5 mouse 
heart sections for (A) HCN4 (Arrow depicts SAN myocytes, 
and arrowhead indicates presumptive AYN myocytes), and 
(B) Sarcomeric a-actinin. RA, right atrium; RV, right ven-
tricle. Scale bar, 1.0 mm. (C--H) Frontal series of E15.5 
Pnmt-Cre/R26R heart sections stained for expression of Lacz 
(C-E) and the pacemaker channel protein, HCN4 (panels G & 
H). An expanded view of the boxed region (SAN) in panel E 
50 arrows indicate uncertainty about the number of steps 
required in between the specified cell types shown. Abbrevia-
tions, CS, cardiac stem; CMS, cardiomyocyte stem; SAN, 
sinoatrial node; AYN, atrioventricular node; His, H bundle; 
Pur, Purkinje fiber. 
is shown in panel F. Upon switching to dark-field fluores- 55 
cence microscopy with FITC filters, HCN4 staining can be 
seen in this section (panel G). To evaluate co-staining for 
XGAL and HCN4 in this section, the images in panels F and 
FIGS. 14A-14F are cartoon depictions of a proposed 
method for molecular imaging. (A) Pluripotent recombinant 
mouse ES cells (Pnmt-GFP/aMHC-Luc) are expanded in 
culture, dispersed, and induced to differentiate into beating 
cardiac cells using the hanging ball method. (B) During the G were combined to produce the Overlay image depicted in 
panel H. Abbreviations, Ao, aorta, Ao V, aortic valve, MiV, 
mitral valve; SAN, sinoatrial node (boxed region of panels E 
& F). Scale bar (for panels F--H), 0.1 mm. 
FIGS. SA-SE show Lacz expression patterns in neonatal 
mouse heart I: SAN region. (A) Low magnification ( 4x objec-
tive) frontal view of an XGAL-stained Pnmt-Cre/R26R heart 
section at P2. The SAN region is boxed. Scale bar, 1.0 mm. 
(B-E) Higher-magnification (20x objective) view of the 
60 differentiation process, a heterogenous mixture of cells rep-
resenting various developmental potentials emerges. Appli-
cant has colored the nuclei to represent some of the expected 
and observed cellular phenotypes: Black=pluripotent stem 
cell (i.e., undifferentiated, as in 'A'); Grey, cardiac stem (CS) 
65 cell (multipotent cell capable of becoming cardiac myocytes, 
smooth muscle, and endothelial cells (see FIG. 13); 
Green=cardiomyocyte stem (CMS) cell (identified by Pnmt-
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EGFP+ expression in nuclei-also see FIG.17); Red=beating 
cardiomyocytes. There are other cell types (endothelial, 
fibroblast, etc.) arising in these cultures, but only a few rep-
resentative cell types are shown to illustrate the basic idea. (C) 
While in culture, the cardiac--differentiated cells are loaded 
with magnetic microsphere particles (for subsequent MRI in 
vivo) and subjected to fluorescent-activated cell sorting 
(FACS) to selectively isolate CMS (GFP+) cells loaded with 
magnetic particles conjugated to a different fluorophore 
("Dragon Red"). (D) These isolated CMS cells are then be 10 
transplanted into areas of mouse hearts damaged by experi-
mentally-induced myocardial infarction (MI), where they are 
tracked in vivo over the next several days/weeks using MRI. 
(E) To determine ifthe transplanted CMS cells differentiate 
15 
into cardiomyocytes in vivo, Applicant monitors the mice for 
activation of the luciferase reporter gene driven from the 
cardiac a-myosin heavy chain ( aMHC) promoter using in 
vivo bioluminescent imaging (BLI) techniques. (F) System-
atic optimization of each step in this process is expected to 20 
ultimately lead to successful repair/regeneration of damaged 
cardiac muscle tissue and significant improvement in cardiac 
performance (as represented by the Mighty Mouse™ pic-
ture). 
FIGS. 15A-15C show effect of the catecholamine-deplet- 25 
ing agent reserpine on the maintenance of beating rate in 
neonatal rat cardiomyocyte cultures. Spontaneously beating 
neonatal rat cardiomyocytes were allowed to develop for a 
period of7 din culture, and different concentrations of reser-
pine were added directly to the culture media in each well, as 30 
indicated. (A) Beating rates were measured at the indicated 
time points in the presence of the indicated concentrations of 
reserpine (n=6/group ). After the measurement at the 8-h time 
point, the reserpine-containing media was removed (indi-
cated by arrow with designation, "Drug Removal"), the cells 35 
were rinsed with drug-free media, and replenished withdrug-
free growth media. Beating rate measurements were then 
re-evaluated at the 24-h time point. (B) Sample recording of 
beating activity after 8 h of reserpine (2.5 µM) treatment in 
one well. (C) Effect of norepinephrine (NE, 1 µM) on the 40 
beating activity of the same cells recorded in pane B approxi-
mately 2 min after the addition of NE (before removal or 
reserpine). Upper trace in panels B and C represents the 
"event detector signal" used to measure rate. Lower 
trace in same panels represents the actual photodiode sig- 45 
nal. *p<0.05; **p<0.01. 
FIGS.16A-16B show effects ofadrenergic antagonists on 
beating rates in cultured neonatal rat cardiomyocytes. Cardi-
omyocytes were allowed to develop spontaneous beating 
activity over a period of7 d before the addition of drugs. Each 50 
drug was added at the indicated concentrations and beating 
rates were assessed within 1-2 min after drug addition. (A) 
Effect of increasing concentrations of the a 1 -selective 
antagonist prazosin. (B) Effect of increasing concentrations 
of the ~-selective antagonist timolol. **p<0.01 (n=6/group). 55 
FIG. 17 shows effect of ~-adrenergic blockade on beating 
rates in neonatal rat cardiomyocytes cultured using media 
containing charcoal-striped serum. Neonatal rat cardiomyo-
cytes were allowed to develop spontaneous beating activity 
under normal growth conditions for a period of7 d. On d 7, the 60 
culture media was replaced with media containing charcoal-
stripped serum to remove any residual catecholamines that 
may have been present in the serum. Timolol (10 µM) was 
added to the culture medium containing the charcoal-stripped 
serum on half of the cultures at the time of media change on 65 
d 7. Beating rates were then assessed at 24 and 72 h after drug 
treatment (cells were cultured in the continuous presence of 
8 
timolol). Addition of epinephrine (1 µM) enabled full recov-
ery of beating rate for at least 30-60 min. * * *p<0.001 relative 
to control (n=6/group). 
FIG. 18 shows effect of a 1 -adrenergic blockade on the 
beating rates in neonatal rat cardiomyocytes cultured in 
media containing charcoal-stripped serum.Application of the 
a 1 -antagonist, prazosin (1 µM) resulted ina significant reduc-
tion in the beating rate compared with baseline control. This 
reduction in the beating rate was reversed by the addition of 
the a 1 -agonist, L-phenylephrine (L-PE) at the indicated con-
centrations. **p<0.01; ***p<0.001 (n=12/group ). 
DETAILED DESCRIPTION OF THE INVENTION 
The invention is based, at least in part, on Applicant's 
discovery that the epinephrine biosynthetic enzyme, phenyle-
thanolamine n-methyltransferase (Pnmt), is a novel marker 
for cardiomyocyte progenitor cells in the developing heart. As 
described in the working examples, Applicant created a novel 
mouse model that enabled Applicant to follow the fate of 
intrinsic cardiac adrenergic (ICA) cells in the developing 
heart. This was accomplished through targeted insertion of 
the Cre-recombinase gene into the locus encoding for Pnmt, 
followed by crossing the resulting Pnmt-Cre mice with 
ROSA26 reporter (R26R) mice such that expression of Lacz 
(encoding ~-galactosidase) was activated in cells that were 
selectively derived from the adrenergic lineage. 
Pnmt is an enzyme that converts norepinephrine (NE) to 
epinephrine (EPI). EPI and NE are the major circulating 
catecholamines in most mammals. In adults, they are prima-
rily produced in adrenergic neurons and adrenal chromaffin 
cells by the enzymatic conversion of the amino acid, L-ty-
rosine. The catecholamine biosynthetic pathway is shown 
below. The enzymes that catalyze each reaction are shown in 
italics above the arrows between precursors and products 
(TH, tyrosine hydroxy lase; L-AAAD, L-aromatic amino acid 
decarboxylase; DBH, dopamine ~-hydroxylase; PNMT, phe-
ny lethanolamine N-methy ltransferase). 
##S TROOOO 1 ## 
During periods of acute stress, EPI and NE are important 
modulators of"fight or flight" responses. Their actions induce 
significant metabolic and physiologic responses, especially 
in the cardiovascular system where they strongly increase 
cardiac output by stimulating both the rate and force of car-
diac contractions. NE and/or EPI are also essential for fetal 
development because mice that lack the ability to produce 
these neurotransmitter hormones die from cardiovascular 
failure (Thomas et al., 1995, Nature 374:643-646). 
In certain embodiments, the present invention relates to 
identification of a population of progenitor or stem cells that 
can be used in repair and/or regeneration of diseased or dam-
aged tissue, such as the heart, brain, lungs, liver, kidney, 
adrenal glands, testes, retina, and possibly other cells/tissues/ 
organs that have yet to be identified. Applicant's findings 
indicate that the Pnmt gene can be used as a specific marker to 
identify such progenitor/stem cells. These findings may sig-
nificantly advance repair and regeneration studies by allow-
ing isolation of the progenitor/stem cells easily and quickly 
by using Pnmt as a specific marker for this population of cells, 
which can then be used in a clinical setting to facilitate repair 
and regeneration of damaged tissue. 
Pnmt-Positive Progenitor Cells 
In certain embodiments, the present invention provides 
isolated Pnmt-positive mammalian progenitor cells. For 
example, Applicant identified a subclass of cardiac cells that 
have the functional and molecular characteristics of progeni-
tor cells. In particular, these newly discovered cardiac pro-
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genitor cells are characterized by expression of Punt, and the 
ability to differentiate into cardiomyocytes. The present 
inventors also identified a subclass of Pnmt-positive neural 
cells that are neural progenitor cells. 
In certain embodiments, the Pnmt-positive progenitor cells 
can be isolated from or derived from various stem cell cul-
tures (e.g., adult bone marrow-derived stem cells, adipose-
derived stem cells, cardiac-derived stem cells, neural-derived 
stem cells, embryonic stem cells, etc.). Alternatively, the 
Pnmt-positive progenitor cells can be isolated from develop-
ing (e.g., embryonic) or adult tissue/organs. In certain cases, 
the subject progenitor cells differentiate into adrenergic cells. 
In certain other cases, the subject progenitor cells (defined by 
their ability to express Pnmt) transiently differentiate into 
adrenergic-like cells followed by further differentiation into 
cardiomyocytes, neuronal, and/or other specialized cell 
types. 
As used herein, the term "progenitor cell" or "precursor 
cell" refers to a cell that is derived from a stem cell by 
differentiation and is capable of further differentiation to 
more mature cell types. A "stem cell," as used herein, refers to 
a cell which is capable of essentially unlimited propagation 
either in vivo or ex vivo and differentiates to other cell types. 
Generally, stem cells can divide without limit. After division, 
the stem cell may remain as a stem cell, become a precursor 
cell or progenitor cell, or proceed to terminal differentiation. 
Although appearing morphologically unspecialized, the stem 
cell may be considered differentiated where the possibilities 
for further differentiation are limited. 
As used herein, differentiation refers to the process 
whereby relatively unspecialized cells (e.g., stem cells or 
progenitor cells) acquire specialized structural and/or func-
tional features characteristic of mature cells. Similarly, "dif-
ferentiate" refers to this process. Typically, during differen-
tiation, cellular structure alters and tissue-specific proteins 
appear. 
10 
invention can be identified by their expression of Pnmt (e.g., 
by FACS, immunocytochemical staining, RT-PCR, Southern 
Northern and Western blot analysis, and other such tech-
niques of cellular identification as known to one skilled in the 
art). 
For example, immunocytochemical staining can be carried 
out according to the following method. Heart tissues or cells 
are incubated with a primary antisera to the Pnmt protein. The 
antisera is rinsed off with PBS and incubated with the appro-
10 priate fluorescently labeled secondary antisera. Fluorescence 
microscopy is then performed to identify Pnmt-positive pro-
genitor cells. Antisera useful according to the invention 
include monoclonal and polyclonal antibodies. 
RT-PCR and Southern blot analysis are well known in the 
15 art. To illustrate, total cellular RNA prepared from heart tis-
sues or cells is reverse-transcribed and amplified by PCR for 
about 35 cycles depending on the desired degree of amplifi-
cation. The RNA samples are then either PCR-amplified with 
oligonucleotide primers for RT-PCR or probed with oligo-
20 nucleotide probes for subsequent Southern blot hybridiza-
tion. Sequences of the oligonucleotides are considered to be 
within the scope of the art. As a general guide, primers are 
selected from two different exons and encompass at least one 
intronic sequence of the Pnmt gene. 
25 Methods of Isolation and Transplantation 
In certain embodiments, the present invention relates to 
methods of isolating and transplanting Pnmt-positive pro-
genitor cells, such as cardiac progenitor cells. As described 
above, the Pnmt-positive progenitor cells can be isolated from 
30 various pluripotent stem cell cultures (e.g., adult bone mar-
row-derived stem cells, adipose-derived stem cells, cardiac-
derived stem cells, neural-derived stem cells, embryonic stem 
cells, etc.), or from developing (e.g., embryonic) or adult 
tissue/organs (e.g., heart). The isolated progenitor cells can 
35 then be expanded ex vivo and the resulting cells transplanted 
back into the donor as an isograft. In the donor, the trans-
planted Pnmt-positive progenitor cells may differentiate to 
provide, for examples, cardiomyocytes to replace cardiomyo-
In certain specific embodiments, the invention provides 
compositions or formulations comprising a Pnmt-positive 
progenitor cell and a physiologically compatible carrier. As 
used herein, "physiologically compatible carrier" refers to a 40 
physiologically acceptable diluent such as water and physi-
ologically compatible buffers (e.g., phosphate buffered 
saline, Hank's solution, Ringer solution, or physiologically 
buffered saline). 
cytes such as those lost due to myocardial injury. 
"Isolating" a progenitor cell refers to the process of remov-
ing a progenitor cell from a tissue sample and separating away 
other cells which are not progenitor cells of the tissue. An 
isolated progenitor cell is generally free from contamination 
by other cell types and generally has the capability of propa-
In one embodiment, the invention provides Pnmt-positive 
progenitor cells for a variety of applications, including but not 
limited to, cellular replacement therapy for myocardial inju-
ries and neurodegenerative disorders. The Pnmt-positive pro-
genitor cells of the invention can also be used to carry out 
gene therapies in isograft, allograft or xenograft transplanta-
tions. As used herein, "allogeneic" refers to genetically dif-
ferent members of the same species; "isogeneic" refers to 
individuals of identical genetic constitution; and "xenoge-
neic" refers to members of a different species. 
In another embodiment, the Pnmt-positive progenitor cells 
described herein can be used to produce recombinant cells, 
artificial tissues, and replacement organs in culture. They can 
also be used for the ex vivo production of catecholamines 
such as adrenaline (epinephrine). Molecular characteristics 
of the subject Pnmt-positive progenitor cells, such as cardiac 
progenitor cells, can be used in various diagnostic, pathologi-
cal, or investigative procedures to identify, localize, and quan-
titate progenitor cells in tissues from a patient or experimental 
animal. 
In certain embodiments, the present invention relates to 
methods of identifying Pnmt-positive progenitor cells, such 
as cardiac progenitor cells. Progenitor cells of the present 
45 gation and differentiation to produce mature cells of the tissue 
from which it was isolated. However, when dealing with a 
collection of progenitor cells, e.g., a culture of progenitor 
cells, it is understood that it is practically impossible to obtain 
a collection of progenitor cells which is 100% pure. There-
50 fore, an isolated progenitor cell can exist in the presence of a 
fraction of other cell types which do not interfere with the 
utilization of the progenitor cell for analysis or production of 
other, differentiated cell types. Isolated progenitor cells are 
generally at least 30%, 40%, 50%, 60%, 70%, 80%, 85%, 
55 90%, 95%, 98%, or 99% pure. Preferably, isolated progenitor 
cells according to the invention are at least 98% or at least 
99% pure. 
A progenitor cell is "expanded" when it is propagated in 
culture and gives rise by cell division to other progenitor cells. 
60 Expansion of progenitor cells may occur spontaneously as 
progenitor cells proliferate in a culture or it may require 
certain growth conditions, such as a minimum cell density, 
cell confluence on the culture vessel surface, or the addition of 
chemical factors such as growth factors, differentiation fac-
65 tors, or signaling factors. 
A progenitor cell or differentiated cell is transplanted or 
introduced into a mammal when it is transferred, for example 
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from a culture vessel into a subject (individual or patient). 
Transplantation, as used herein, can include the steps of iso-
lating a progenitor cell according to the invention and trans-
ferring the progenitor cell into a subject Transplantation can 
involve transferring a progenitor cell into a subject by injec-
tion of a cell suspension into the subject, surgical implanta-
tion of a cell mass into a tissue or organ (e.g., heart) of the 
subject, or perfusion of a tissue or organ with a cell suspen-
sion. The route of transferring the progenitor cell or trans-
plantation is determined by the need for the cell to reside in a 10 
particular tissue or organ and by the ability of the cell to find 
and be retained by the desired target tissue or organ. In the 
case where a transplanted cell is to reside in a particular 
location, it can be surgically placed into a tissue or organ or 
15 
simply injected into the bloodstream ifthe cell has the capa-
bility to migrate to the desired target organ. 
In certain embodiments, the present invention relates to 
methods of overcoming the problems of immune rejection 
resulting from transplantation of tissue. In one embodiment, 20 
the use of isografted progenitor cells makes it possible to alter 
the transplanted cells to render them or less likely to cause 
immune reaction. A further advantage of using progenitor 
cells, rather than an intact heart, is that transplanted progeni-
tor cells can differentiate in situ and better adapt to the host 25 
environment. Another embodiment of the invention contem-
plates the use of partially differentiated progenitor cells ex 
vivo, for example, to form progenitor cells, which are subse-
quently transplanted into the host, with further differentiation 
taking place within the host. 30 
In a specific embodiment, Pnmt-positive progenitor cells 
of the invention are immunologically blind or immunoprivi-
leged. For example, immunoprivileged progenitor cells do 
not express sufficient amounts of class I and/or class II major 
35 
histocompatibility (MHC) antigens (also referred to as HLA 
12 
Methods of Molecular Imaging 
In certain embodiments, the present invention provides 
methods of assessing a Pnmt-positive cardiac progenitor cell 
for its ability to regenerate cardiac tissues in vivo. For 
example, in such methods, a Pnmt-positive cardiac progenitor 
cell is obtained and transferred into a subject in need thereof. 
The fate of the transferred progenitor cell is then monitored in 
vivo. In certain cases, the transferred progenitor cell contains 
a marker, such as GFP, luciferase, and beta-galactosidase. To 
illustrate, the transferred progenitor cell can be monitored 
(tracked) by magnetic resonance imaging (MRI) or by biolu-
minescence imaging (BLI). 
Development and application of non-invasive imaging 
techniques to physically and functionally assess the potential 
of novel cardiac progenitor cells to regenerate damaged myo-
cardium has clear clinical significance. Repair and replace-
ment of damaged cardiac muscle tissue is a key limitation in 
the prognosis for recovery from ischemic and other forms of 
heart disease. There is a great need for new approaches to this 
enduring problem, since heart disease is the leading killer in 
the United States. New strategies for regenerating damaged 
cardiac muscle could be readily translated to the clinical 
setting if first shown to be effective in animal models. 
Accordingly, the present invention relates to use of 
molecular imaging techniques in vivo to evaluate the novel 
progenitor cell-based strategy for cardiac regenerative medi-
cine. Specifically, this application contemplates methods for 
detecting and quantifying molecular and cellular pathways 
that regulate heart function, and methods for cell tracking in 
vivo for applications in cell-based therapeutics. For example, 
cardiac progenitor cells of the invention can be transplanted 
into damaged hearts and these cells can be tracked in vivo 
using modified magnetic resonance and bioluminescent 
imaging methods. 
One specific embodiment of the invention is a method of 
identifying and selecting cardiac progenitor cells based on 
their ability to express knock-in reporter genes from the 
endogenous Pnmt gene locus. These cells can be isolated in 
vitro, loaded to magnetic microsphere particle beads, and 
or human leukocyte antigen) to elicit an immune response 
from the host. Progenitor cells obtained from allogeneic or 
xenogeneic sources do not initiate a host versus graft response 
in immunocompetent transplant recipients. 40 transplanted into regions of the heart damaged by myocardial 
infarction. Thus, another embodiment of the invention pro-
vides methods of molecular imaging of cardiomyocytes pro-
genitor cells (the method is also referred to as cardiac imag-
As a non-limiting example, Pnmt-positive progenitor cells 
are isolated, cultured, and maintained in vitro. They can be 
obtained from tissue or from existing stem cell lines. Using 
genetic engineering techniques, the Pnmt-positive progenitor 
cells are engineered to express a reporter gene, such as 45 
enhanced green fluorescent protein (EGFP), beta-galactosi-
dase gene, firefly luciferase gene, or other similar type of 
reporter, from the endogenous Pnmt locus. Differentiation of 
the progenitor cells is then initiated along pathways leading to 
the preferential development of specific cell and tissue types 50 
(e.g., cardiac, neural, renal, pulmonary or hepatic). Pnmt-
linked reporter gene expression are used to isolate specific 
progenitor cells using fluorescence-activated cell sorting 
(FACS) or other methodology following induction of differ-
entiation towards specific cell types in vitro. The Pnmt-posi- 55 
tive cells are transplanted into or near damaged or diseased 
tissues. Targeted disruption of one or both Pnmt alleles does 
not appear to be detrimental, which is an advantage of using 
Pnmt as a marker. To avoid cell/tissue rejection, expression 
from the major histocompatibility (MHC) locus can be dis- 60 
rupted. Alternatively, the nuclear transfer technique can be 
employed to convert recipient progenitor cells into host cells 
by replacing the progenitor cell nuclei with nuclei isolated 
from the individual destined to receive the transplant. Typi-
cally, the nuclear transfer step is performed prior to engineer- 65 
ing the progenitor cells to express a reporter gene from the 
Pnmtlocus. 
ing) to track and study the functional development of these 
novel progenitor cells in vivo. Optionally, the subject meth-
ods of cardiac imaging are performed in small animals. 
In certain embodiments, the present invention includes 
application of non-invasive molecular and cellular imaging 
techniques that would facilitate development and character-
ization of progenitor cell strategies in the heart because they 
permit repeated assessments of the transplanted cells in vivo 
without the need to sacrifice the animals or subject them to 
complicated invasive procedures. Several different in vivo 
imaging approaches have been developed, such as MRI and 
BLI. 
MRI has been used for many years to assess anatomical and 
physiological parameters in vivo; however, the use of MRI to 
follow (track) specific cell populations in the cardiovascular 
system has only recently been described in a few published 
reports. Of particular interest for Applicant is the discovery 
that it is possible to "load" cells with magnetic nanoparticles 
(e.g., ferrodex) in vitro and track these cells with MRI after 
they have been transplanted into the heart (or other organs/ 
tissues) in vivo. Remarkably, cells loaded with these mag-
netic particles appear to be relatively stable in vivo, which 
makes it possible to track transplanted cells over several days, 
weeks, and perhaps months. 
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In contrast to MRI, BLI technology is primarily based on 
the ability to detect light emitted from expression of the firefly 
luciferase reporter gene in the presence of the substrate, 
luciferin. Although this technology has been used for many 
years as a way to quantitate reporter gene activity in tran-
siently transfected cells in vitro, only recently has it been 
adapted for in vivo imaging applications. Several studies 
have, for example, demonstrated that luciferase activity can 
be detected in anesthetized mice using a specialized ccd vid-
eocamera set-up ina darkroom. To date, most of these studies 10 
have fused a strong viral promoter to drive high levels of 
luciferase activity in target tissues. Certain embodiments of 
the invention contemplate fusion of strong cell type-specific 
promoters to luciferase so that the differentiation state of 
transplanted cells can be assessed by evaluating activation of 15 
luciferase expression over time in vivo using BLI. 
Methods of Treatments 
14 
dysfunction. Heart failure generally refers to the inability of 
the heart to supply sufficient oxygenated blood to meet the 
metabolic needs of the tissues and cells in an individual. This 
can be accompanied by circulatory congestion, such as con-
gestion in the pulmonary or systemic veins. As used herein, 
the term heart failure encompasses heart failure from any 
cause, and is intended herein to encompass terms such as 
"congestive heart failure," "forward heart failure," "backward 
heart failure," "high output heart failure," "low output heart 
failure," and the like. Conditions that could lead to heart 
failure include, but are not limited to, coronary artery disease, 
cardiomyopathy, or congenital heart disease. 
Cardiac dysfunction is understood to include any impair-
ment in the heart's pumping function. This includes, for 
example, impairments in contractility, impairments in ability 
to relax (sometimes referred to as diastolic dysfunction), 
abnormal or improper functioning of the heart's valves, dis-
eases of the heart muscle (sometimes referred to as cardiomy-
opathy ), diseases such as angina and myocardial ischemia 
In certain embodiments, the present invention provides 
methods of preventing or correcting developmental defects 
(e.g., cardiac or neuronal), or treating complications ( condi-
tions, disorders or diseases) arising later in life. Such methods 
involve administering to a subject in need thereof the Pnmt-
positive progenitor cells of the invention. 
In one embodiment, the Pnmt-positive progenitor cells of 
the invention are useful to replace lost cardiomyocytes or to 
increase the overall numbers of cardiomyocytes in patients 
suffering from a myocardiac injury. Myocardial injury refers 
20 and infarction characterized by inadequate blood supply to 
the heart muscle, infiltrative diseases such as amyloidosis and 
hemochromatosis, global or regional hypertrophy (such as 
may occur in some kinds of cardiomyopathy or systemic 
hypertension), and abnormal communications between 
to damage to the muscle or the "myocardium" in the wall of 
the heart as a result of disease or trauma. Myocardial injury 
can be attributed to many things, such as cardiomyopathy, 
myocardial infarction, or congenital heart disease. 
25 chambers of the heart (for example, atrial septa! defect). See 
Braunwald, Heart Disease: a Textbook of Cardiovascular 
Medicine, 5th edition 1997, W B Saunders Company, Phila-
delphia Pa. (hereinafter Braunwald). 
In another embodiment, the Pnmt-positive progenitor cells 
30 of the invention are useful to replace lost neuronal cells or to 
increase the overall numbers of neuronal cells in individuals 
A "cardiomyocyte" is a cell of the cardiac muscle that is 
striated like skeletal muscle, having microscopically visible 
myofilaments arranged in parallel with the sarcomere. Car-
diac muscle can generate its own excititory impulses from the 35 
sino-atrial node, which acts like a biological pacemaker. In 
this manner, the contracting signal for cardiac muscles origi-
nates in the heart itself. However, the autonomic nervous 
system can exert control over how fast the signals form and 
propagate through the heart, which regulates the rate of myo- 40 
cardial contraction. 
Cardiomyopathy refers to any disease or dysfunction of the 
myocardium (heart muscle) in which the heart is abnormally 
enlarged, thickened and/or stiffened. As a result, the heart 
muscle's ability to pump blood is usually weakened. The 45 
disease or disorder can be, for example, inflammatory, meta-
bolic, toxic, infiltrative, fibroplastic, hematological, genetic, 
or unknown in origin. There are two general types of cardi-
omyopathies: ischemic (resulting from a lack of oxygen) and 
non-ischemic. Ischemic cardiomyopathy is a chronic disor- 50 
der caused by coronary artery disease-a disease in which 
there is atherosclerotic narrowing or occlusion of the coro-
nary arteries on the surface of the heart. Coronary artery 
disease often leads to episodes of cardiac ischemia, in which 
the heart muscle is not supplied with enough oxygen-rich 55 
blood. Eventually, the heart muscle enlarges from the addi-
tional work it must do in the absence of sufficient oxygen-rich 
blood. 
in order to treat neurodegenerative disease (disorder or con-
dition) and neurological trauma. Examples of neurodegen-
erative diseases include, but are not limited to, Huntington's 
Disease (HD), Alzheimer's Disease (AD), and Parkinson's 
Disease (PD). The Pnmt-positive progenitor cells can be 
transplanted into any area from which neural progenitor cells 
can be obtained that serves to restore function to a degener-
ated area of the host's nervous system, particularly the host's 
central nervous system (CNS). To illustrate, suitable areas 
include the cerebral cortex, cerebellum, midbrain, brainstem, 
spinal cord and ventricular tissue. 
In certain embodiments, the present invention relates to use 
of Pnmt-positive progenitor cells that are immunologically 
blinded or immunoprivileged, such that in allogeneic or xeno-
geneic transplants, they are recognized as self by the recipi-
ent, and are not MHC restricted by class I or class II antigens. 
For example, these cells do not express MHC class I and/or 
class II antigens. Alternatively, progenitor cells isolated from 
a non-human mammal according to the invention are trans-
planted into a human subject. Prior to the transplantation step, 
the progenitor cells may be cultured, and/or expanded and/or 
differentiated. 
In certain embodiments, the progenitor cells of the inven-
tion can be treated by gene therapy to correct a genetic defect 
and introduced into a patient to restore cardiac or neuronal 
function. 
In one embodiment of the invention, the Pnmt-positive 
progenitor cells can be differentiated either in culture or in Congenital heart disease refers to a condition that is present 
at birth and often as the heart is forming even before birth. 
Congenital heart disease may affect the heart, the heart's 
valves, the veins leading to, or the arteries leading away, from 
the heart, or the connections between these parts of the body. 
60 vivo by applying one or more growth factors, or other treat-
ments such as transfection with a nucleic acid molecule, that 
results in differentiation of the progenitor cells to cardiomyo-
cytes or neuronal cells. 
Accordingly, in certain embodiments, the present inven-
tion provides methods of treating or preventing heart disor-
ders such as cardiomyopathy, myocardial infarction, con-
genital heart disease, heart failure, and any kind of cardiac 
In another embodiment of the invention, the Pnmt-positive 
65 progenitor cells can be transplanted without any ex vivo treat-
ment and the appropriate growth factors can be provided in 
situ within the patient's body. In yet another embodiment, the 
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progenitor cells can be treated with growth factors or other 
agents ex vivo and subsequently transplanted into the patient 
in a partially differentiated or terminally differentiated state. 
Other aspects of the invention include methods oftransfect-
ing progenitor cells, dosages and routes of administration, 
pharmaceutical compositions, donor-isograft protocols, and 
immunosuppression methods. 
16 
fold. Bioresorbable materials are well known in the art, 
including, for example, poly(lactic acid), poly(glycolic acid), 
polydioxanone, polyhydroxybutyrate, and poly(trimethylene 
carbonate), or mixtures thereof. Poly(lactic acid) has good 
mechanical strength and does not resorb quickly. Thus, its 
mechanical properties can be retained for a time sufficient for 
tissue in-growth to occur (at which point the tissue can 
assume some, if not all, of the load-bearing function of the 
scaffold (see A. G. A. Coombes and M. C. Meikle, "Resorb-
The invention specifically contemplates transplanting into 
patients isogeneic, allogeneic, or xenogeneic progenitor 
cells, or any combination thereof. 
Mode of Administration 
10 able Synthetic Polymers as Replacements for Bone Graft," 
Clinical Materials, 17:35-67, 1994). 
In certain embodiments, the present invention provides 
methods of treating a disease or a tissue injury by delivering 
the Pnmt-positive progenitor cell to a diseased or injured 
target tissue (e.g., heart). In certain specific aspects, the 
present invention provides composition and methods of tissue 
engineering. Tissue engineering provides the opportunity to 
generate living substitutes for tissues and organs, which may 
overcome the drawbacks of classical tissue reconstruction. 
Optionally, the method can be used alone or in combination 20 
with other therapies. 
Non-bioresorbable materials are also well known in the art, 
including, for example, polyesters, particularly aromatic 
polyesters, such as polyalkylene terephthalates; polyamides; 
15 polyalkenes such as polyethylene and polypropylene; poly 
(vinyl fluoride), polytetrafluoroethylene carbon fibres; silk 
(natural or synthetic); carbon fibre; glass; and mixtures of 
these materials. An advantage of non-bioresorbable materials 
In one embodiment, the present invention provides a tissue 
engineering composition which comprises: a) a Pnmt-posi-
tive progenitor cells; and b) a biocompatible scaffold. Such 
tissue engineering composition generates a scaffold graft to 25 
be delivered to a target tissue. 
In certain embodiments, the present invention provides a 
method of delivering a scaffold graft in a target tissue, com-
prising: a) seeding the Pnmt-positive progenitor cell onto a 
scaffold, thereby forming a scaffold graft; and b) implanting 30 
the scaffold graft from (b) in direct contact with, or adjacent 
is that they essentially retain their initial mechanical proper-
ties. 
In certain embodiments, the biocompatible scaffold can 
include certain additional components. For example, the scaf-
fold may include bioactive factors, such as growth factors, 
hormones, catecholamines (norepinephrine or epinephrine), 
extracellular matrix proteins, cytokines or chemokines. 
In other embodiments, hydrogels can also be included in 
the biocompatible scaffold. For example, the hydrogel can be 
incorporated within and/or around the scaffold prior to 
implantation to facilitate the transfer of cells and other bio-
logical material (e.g., growth factors) from the surrounding 
tissue into the scaffold. Hydro gels include positively charged, 
negatively charged, and neutral hydrogels, and can be either 
saturated or unsaturated. Examples of hydrogels are 
TETRONICS™ and POLOXAMINES™, which are poly 
( oxyethylene )-poly( oxypropylene) block copolymers of eth-
ylene diamine; polysaccharides, chitosan, poly(vinyl 
amines), poly(vinyl pyridine), poly(vinyl imidazole), poly-
ethylenimine, poly-L-lysine, growth factor binding or cell 
adhesion molecule binding derivatives, derivatized versions 
to, a target tissue for a sufficient time, wherein cells of the 
target tissue associate with the implanted scaffold graft, 
thereby to form new tissue. For example, the scaffold graft 
can be delivered in a heart tissue by surgical implantation. 35 
Optionally, such methods may further comprise removing the 
scaffold graft from the subject. For example, the scaffold graft 
removed from the subject (i.e., the scaffold and the tissue it 
bears at the end of the implantation period) can then be 
re-grafted into another target tissue. 40 of the above (e.g., polyanions, polycations, peptides, polysac-
charides, lipids, nucleic acids or blends, block-copolymers or 
combinations of the above or copolymers of the correspond-
ing monomers); agarose, methylcellulose, hydroxyproylm-
As described herein, the biocompatible scaffold can con-
sist of bioresorbable or non-bioresorbable materials. If the 
scaffold consists of a single bioresorbably material, it is pref-
erably one that does not significantly resorb during the period 
of time when the target tissue is being laid down on or within 45 
it. Such scaffolds generate a scaffold graft that includes living 
cells and essentially retain their shape and mechanical integ-
rity. In some instances, it may be preferable to use scaffolds 
containing bioresorbable materials that lose, for example, 
less than a 2% of their weight during the same period. If the 50 
scaffold is constructed with two or more bioresorbable mate-
rials, it may be preferable to select the bioresorbable material 
that provides the scaffold with its structural integrity accord-
ing to these criteria. 
In certain embodiments, the bioresorbable materials for the 55 
biocompatible scaffold include bioresorbable polymers or 
copolymers that comprise the following monomers or mix-
tures of polymers and/or copolymers formed thereby: 
hydroxy acids, particularly lactic acid; glycolic acid; capro-
lactone; hydroxybutyrate; dioxanone; orthoesters; orthocar- 60 
bonates; aminocarbonates. 
Optionally, the bioresorbable materials can also include 
natural materials such as collagen, cellulose, fibrin, hyalu-
ronic acid, fibronectin, chitosan, or mixtures of two or more 
of these materials. The bioresorbable materials may also 65 
comprise devitalized xenograft and/or devitalized allograft. 
Bioresorbable ceramics can also be included within the scaf-
ethylcellulose, xyloglucan, acetan, carrageenan, xan-
thangum/locust beangum, gelatine, collagen (particularly 
Type 1), PLURONICS™, POLOXAMERS™, POLY(N-iso-
propylacrylmide), and N-isopropylacryhnide copolymers. 
EXEMPLIFICATION 
The following materials and methods were used in carrying 
out the work described herein. The invention now being gen-
erally described, it will be more readily understood by refer-
ence to the following examples, which are included merely 
for purposes of illustration of certain aspects and embodi-
ments of the present invention, and are not intended to limit 
the invention. 
Example 1 
PNMT is a Novel Marker for Cardiomyocyte Progenitor 
Cells 
1. Introduction 
Epinephrine (EPI) and norepinephrine (ME) are the major 
peripheral catecholamines produced in mammals. They are 
synthesized via the enzymatic conversion of dopamine to NE 
by the action of dopamine ~-hydroxylase (Dbh) and, subse-
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quently, of NE to EPI by the action of phenylethanolamine 
n-methyltransferase (Pnmt) (Cooper et al., 1991, Norepi-
nephrine and Epinephrine. In The biochemical basis ofneu-
ropharmacology, (New York: Oxford University Press), pp. 
220-284). In adult mammals, this synthesis occurs primarily 
in the adrenal medulla and in the sympathetic nervous system. 
Mice that lack the ability to produce NE and EPI due to 
targeted disruption of the Dbh gene die in utero from apparent 
cardiac failure (Thomas et al., 1995, Nature 374, 643-646). 
The vast majority of Dbh mouse embryos die before the 10 
adrenal gland even forms and before maturation of the sym-
pathetic nervous system, suggesting that the primary 
source(s) of catecholamine biosynthesis in the embryo must 
be different from that in adult mice (Thomas et al., 1995, 
Nature 374, 643-646). One potential source is the heart itself, 15 
where Applicant and others have shown that ICA cells are 
present beginning at relatively early stages (E9 .5 in rat; E3 in 
chick) of cardiac development (Ignarro and Shideman, 1968, 
J. Pharmacol. Exp. Ther. 159, 38-48; Ebert et al., 1996, J. 
Mo!. Cell. Cardiol. 28, 1653-1658; Huang et al., 1996, J. Clin. 20 
Invest 98, 1298-1303; Ebert and Thompson, 2001, Circ. Res 
88, 117-124 ). A specific developmental role for these ICA 
cells remains elusive, but Applicant has recently shown that 
they are transiently and progressively associated with regions 
of the heart that become pacemaking and conduction tissue 25 
(Ebert and Thompson, 2001, Circ. Res 88, 117-124 ). This 
association was initially observed in the sinoatrial node 
(SAN) and atrioventricular canal (AVC) regions at approxi-
mately embryonic day 11.5 (El 1.5) in the rat The clustering 
of ICA cells in these regions then declined over the next 30 
several days of development, but re-appeared along the crest 
of the ventricular septum (bundle of His region) and, some-
what more sporadically, trailing down the ventricular septum 
towards the apex at approximately El6.5. These patterns of 
ICA cell distribution were transient, lasting not more than a 35 
1-2 days in each of these locations. It was not clear if this 
progressive appearance and disappearance of ICA cells in 
these various cardiac regions was due to migration, differen-
tiation, and/or death ofICA cells. 
To help resolve these possibilities, Applicant has <level- 40 
oped a mouse genetic model for studying the fate and function 
of adrenergic cells in vivo. Specifically, the Cre-recombinase 
gene was inserted into the endogenous Pnmt locus (Pnmt-
Cre) so that Cre-recombinase expression would be directed 
by Pnmt regulatory DNA sequences. Upon crossing these 45 
Pnmt-Cre mice to the reporter R26R strain of mice, Applicant 
anticipated activation of Lacz expression exclusively in adr-
energic cells via Cre-mediated recombination of upstream 
1 oxp sites flanking a DNA sequence responsible for blocking 
transcription of the Lacz gene (Soriano, 1999, Nat. Genet. 21, 50 
70-71). In this system, lacZ expression does not require the 
continuous activation of Pnmt-Cre. Rather, the genetic 
changes induced at the Rosa26 locus by transient expression 
of the Cre-recombinase permanently mark the altered cells 
and their descendants as ~-galactosidase positive and, there- 55 
fore, provide a means to follow the fate of adrenergic derived 
cells throughout development In addition, because the tar-
geted insertion of Cre recombinase disrupted the expression 
of the Pnmt gene, Applicant could assess the potential con-
sequences of selective adrenergic deficiency in these mice. 60 
This is the first report to demonstrate that targeted disruption 
of Pnmt gene expression leads to EPI deficiency, and it is also 
the only study to show that the fate of adrenergic cells can be 
effectively mapped in vivo. These efforts have led to the 
rather surprising and novel finding that adrenergic cells con- 65 
tribute much more extensively to myocardial development 
than previously appreciated. 
18 
2. Results 
To determine whether epinephrine plays an important role 
during development and to identify adrenergic cell descen-
dants in the developing mouse, Applicant inserted the Cre-
recombinase gene into the mouse Pnmt locus so the expres-
sion of Cre-recombinase would be dependent upon Pnmt 
regulatory sequences (FIG. lA). Specifically, Applicant 
inserted the Cre-recombinase gene into exon 1, creating a 
gene fusion of the 5' leader sequences from Pnmt directly to 
Cre-recombinase open reading frame. This strategy was 
designed to disrupt functional expression of Pnmt while per-
mitting expression of Cre-recombinase exclusively in adren-
ergic cells. Verification of the correct targeting of the Cre-
recombinase insert was confirmed by Southern blotting using 
5' and 3' probes each external to the targeting vector (FIG. 
lB). 
Two of the correctly targeted clones were further propa-
gated and introduced into mouse blastocysts, and indepen-
dent lines of founder mice were produced. These founder 
mice were crossed with wild type C57B/6 females to generate 
Fl animals used in all subsequent studies. Germ-line trans-
mission of the Pnmt-Cre allele was verified initially by South-
ern blotting and then by PCR (FIG. lC). When Fl heterozy-
gotes were intercrossed, mice harboring the disrupted Pnmt 
allele were born in normal Mendelian ratios. 35+/+:75+/-: 
46-/- were the actual numbers of mice born as compared 
with 39, 78, and 39 mice expected for each genotypic class 
from 156 total progeny (P value=0.410 using the Chi square 
test). The-/- mice appear overtly normal and are fertile even 
in -/-x-/- crosses. 
The absence of Pnmt expression was predicted to result in 
mice that cannot produce epinephrine. To test this hypothesis, 
Applicant measured epinephrine (EPI) and norepinephrine 
(NE) concentrations in adrenal extracts from Pnmt+1+, 
Pnmt+!Cre, and Pnmtcre!Cre mice by radioimmunoassay 
(Table 1 ). EPI was not detectable in extracts from Pnmtcreicre 
mice, and the concentration of NE was found to be signifi-
cantly greater in Pnmtcreicre relative to Pnmt +!+ and 
Pnmt+!cre extracts (P<0.001). In contrast, NE and EPI con-
centrations were similar in extracts from Pnmt+1+ and 
Pnmt+!cre mice. These results show that targeted insertion of 
Cre recombinase effectively disrupted Pnmt expression and 
production ofEPI in homozygous Pnmtcreicre mice, but that 
heterozygous Pnmt+!cre mice were indistinguishable from 
wild-type (Pnmt+1+) mice in terms of adrenal NE and EPI 
content. 
TABLE-US-00001 TABLE 1 Adrenal catecholamine content 
(pg/ng protein). Genotype NE EPI Pnmt+/+ (n=5) 14.2.+-.0.6 
24.6.+-.2.9 Pnmt+!Cre (n=l 0) 17 .8.+-.1.4 25.0.+-.2.8 
Pnmtcre!Cre (n=4) 32.8.+-.2.6*** n.d. n.d. not detected 
(<0.004 pg/ng) ***p<0.001 compared to Pnmt+1+ and 
Pnmt+!Cre 
To map the developmental distribution of Pnmt-Cre-ex-
pressing cells and their descendants, mice heterozygous for 
the insertion (Pnmt+/cre) were mated with R26R mice, 
homozyogous at the ROSA26 reporter locus. Cells in R26R 
mice have the ability to robustly express the bacterial Lacz 
(~-galactosidase) gene if activated by Cre-recombinase (due 
to removal of a floxed transcriptional block) (Soriano, 1999, 
Nat. Genet. 21, 70-71). To determine if applicant's system 
was working, Applicant first examined ~-galactosidase stain-
ing in adrenal glands where the expression patterns of Pnmt 
are well-documented and relatively simple. As illustrated in 
FIG. 2A, Pnmt Immunofluorescent staining is concentrated in 
the adrenal medulla. An adjacent section stained with XGAL 
to detect Lacz expression (blue cells) produced a nearly 
identical pattern of staining (FIG. 2B). When Pnmt immun-
ofluorescent staining was performed on this section after the 
XGAL staining, little or no fluorescently-stained cells were 
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observed because the XGAL blocked or quenched the fluo-
rescence in co-stained cells (FIG. 2C). Thus the localization 
20 
just outside the heart, in both the anterior region adjacent to 
the outflow tract as well as in the posterior region adjacent to 
the atrial chamber (indicated by the arrowheads, FIG. 6C-D). 
The Lacz+ cells (blue) were again found concentrated at 
of Pnmt and ~-galactosidase appear to be completely coinci-
dent here. As a control, the same sections were also stained for 
Th to independently identify chromaffin cells (FIGS. 2D, E, 
F). Th staining was similar to Pnmt and XGAL staining in 
these sections, but there were a few cells that stained posi-
tively for Th that were not stained with XGAL (FIGS. 2E&F, 
arrows). These Th+LacZ- cells presumably represent the 
minority of chromaffin cells that are known to be noradren-
ergic ratherthan the adrenergic majority (Coupland and Tom-
linson, 1989, Int. J. Dev. Neurosci. 7, 419-43; Ebert and 
Thompson, 2001, Circ. Res 88, 117-124). Together, these 
results demonstrate that Lacz expression was highly selective 
in adrenal sections where it was confined to adrenergic 
(Pnmt+) cells. 
5 junction regions, specifically between the atrial, ventricular, 
and outflow tract cavities. 
By El5.5, the heart has matured morphologically to 
assume its adult-like appearance. To determine if Pnmt-ex-
pressing cells contribute to pacemaker cells in the sinoatrial 
10 node (SAN), Applicant performed a preliminary immunof-
luorescent histochemical staining analysis of wild-type El 5 .5 
mouse embryo sections using an antibody that recognizes the 
Hyperpolarization-activated cyclic nucleotide-modulated 
channel isoform 4 (HCN4), a major pacemaker channel pro-
To evaluate Pnmt-Cre expression in the developing mouse 
embryo, applicant performed whole-mount staining with 
XGAL. The earliest stage of development when Lacz expres-
sion could be detected was embryonic day 8.5 (E8.5). Lacz 
expression was observed in the heart (FIG. 3A) and along the 
dorsal ridges of the neural folds in the region of the midbrain-
hindbrainjunction (FIG. 3B). Within the heart, there appears 
15 tein expressed in the SAN (Garcia-Frigola et al., 2003, Gene 
Expr. Patterns. 3, 777-783; Stieber et al., 2003, Proc Natl. 
Acad. Sci. USA 100, 15235-15240). As shown in FIG. 7A, 
HCN4 staining is highly restricted to the SAN region of the 
right atrium (arrow), and to a lesser extent, the AYN region 
20 (arrowhead). In contrast, sarcomeric a-actinin was found to 
be expressed throughout the myocardium in this section (FIG. 
7B). These data confirm that HCN4 was localized to pace-
maker cells in the developing mouse heart. 
to be a small cluster of Lacz+ cells in the sinus venosus region 
(FIG. 3A, arrow), with a few additional Lacz+ cells apparent 25 
in the ascending loop and also near the atrioventricular junc-
tion (see arrowheads, FIG. 3A). 
As shown in the series of sections from a Pnmt-Cre/R26R 
embryo, Lacz expression not only persists in the heart at 
El 5.5, but is highly pervasive throughout the myocardium in 
all four chambers (FIG. 7C-E). By far, the strongest and most 
extensive labeling was found in the ventricular septum, with 
the most prominent staining appearing at the crest of the 
septum and extending laterally into both ventricular cham-
bers along the base as well as caudally down the septum 
towards the apex. Lacz expression in the free walls of both 
chambers was considerably more sparse than that found in the 
septum, with a tendency to be localized in cells near the 
Over the next two days, Lacz expression became much 
more widespread in the heart, as shown in FIG. 4A. By this 
time, Lacz expression was also evident in the brainstem 30 
region, 2nd branchial arch, and sporadically along the dorsal 
surface of the embryo. Lacz expression was dependent upon 
Cre-recombinase expression from the Pnmt locus since none 
was observed when wild-type embryos were similarly 
crossed with R26R mice (FIG. 4B). 
Although it appears from the whole-mount staining (FIG. 
4A) that the entire heart was expressing Lacz at this stage of 
development, examination of heart sections from these 
embryos revealed that the true staining pattern was more 
restricted (FIG. 5). Sporadic staining of cardiac cells was 40 
observed in the atrial and ventricular regions, including cells 
35 endocardial surface, though Lacz+ cells were also clearly 
seen in the mid- and epicardial regions of the ventricular 
myocardium. There appeared to be little or no Lacz expres-
sion in the aorta (Ao), aortic valves (Ao V), and mitral valves 
in the trabecular region of the ventricle. As shown in FIG. 5, 
Lacz expression was observed in the SA junction region 
(FIG. 5A-B); however, the strongest Lacz staining was found 
near the AV and conoventricular junction regions (FIG. 45 
5C-D). These Lacz expression patterns were consistently 
observed at this stage of development, and they appear similar 
(MiV), all of which can be clearly seen as non-stained tissue 
in FIG. 7D; however, the myocardial region immediately 
adjacent to the intake region of each of these valves was 
strongly labeled with blue XGAL stain. 
Within the atria, Lacz expression was sporadic, with the 
majority of atrial myocytes appearing as non-stained cells. 
The exception to this pattern of atrial staining appeared in the 
sinoatrial node (SAN) region where a strong clustering of 
blue Lacz+ cells was evident (FIGS. 7 E & F). To show that 
these cells were SAN myocytes, Applicant performed immu-
nofluorescent histochemical staining of the sections with the 
to the pattern of catecholamine-producing cells previously 
reported at a comparable developmental stage in the rat (Ebert 
and Thompson, 2001, Circ. Res 88, 117-124). 50 anti-HCN4 antibody. As shown in FIGS. 7G & H, HCN4 
expression is robust in this region and overlaps extensively 
with the XGAL staining. These results demonstrate that 
many, but not all, of the presumptive pacemaker cells 
The pattern of Lacz expression in the heart appears to be 
restricted to myocardial cells. To further evaluate this obser-
vation, Applicant performed triple-labeling experiments 
whereby Pnmt-Cre/R26R heart sections (E9.5) were stained 
for expression of (i) a muscle-specific marker, sarcomeric 55 
a-actinin (red fluorescence, FIG. 6A), (ii), Lacz as a marker 
for cells descended from an adrenergic lineage (blue XGAL 
staining, FIG. 6B) and (iii) an adrenergic cell marker, Pnmt 
(green fluorescence, FIG. 6C). Extensive overlap of these 
three staining patterns could be observed by merging the 60 
individual staining panels into a single "overlay" image, as 
shown in FIG. 6D. The yellow regions represent cells that 
co-express a-actinin and Pnmt (arrows point to some 
examples of overlapping expression patterns). Some cells are 
clearly red or green, but many yellow cells can also been seen 65 
in this image. Notably, most of the exclusive green (Pnmt+/ 
a-actinin) cells in the overlay image (FIG. 6D) were found 
(HCN4+) in the SAN also expressed Lacz in these Pnmt-Cre/ 
R26Rmice. 
Although Lacz expression is found in pacemaker cells as 
Applicant has just shown, it is clear from the data presented 
thus far that Lacz expression in the heart extends well beyond 
the SAN region. By El 5.5, most of the Lacz-expressing cells 
are found throughout the myocardium, as indicated above 
(see FIG. 7C-E). 
This pattern of Lacz expression persisted in the heart 
through at least the early postnatal period. As shown in FIG. 
8, extensive XGAL labeling was observed throughout the 
heart, and was especially dense in the ventricular septum. 
Many of the pacemaker cells (HCN4 +)were also stained blue 
with XGAL (FIG. SB-D). Endogenous Pnmt expression in 
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the SAN region was extremely weak at this stage of develop-
ment (Postnatal day 2, P2), being at best confined to a small 
cluster of cells (see arrowhead, FIG. SE). 
3. Materials and Methods 
A) Creation of Pnmt-Cre Knock-in/Knockout Mice 
To construct targeting vector pKP506 Applicant first iso-
lated and subcloned a 7 kb Sad fragment from bacterial 
artificial chromosome 238M20 (Genome Systems). This 
fragment carries Pnmt exon 1 and includes 3 .3 kb upstream of 
the ATG initiation codon and also 3. 7 kb of sequences 3' of the 
translation start site. A 1.4 kb SexAl fragment carrying exon 
1 was next subcloned and mutagenized using the Gene Editor 
Mutagenesis Kit (Promega) to add a unique EcoRI site in 
place of the normal Pnmt translation initiation codon. A cas-
sette carrying the Cre-recombinase gene fused to a nuclear 
localization signal (NLS) was then inserted at this unique 
EcoRI site so that the expected mRNA product is a fusion of 
the Pnmt 5' untranslated leader to sequences encoding the 
Cre-recombinase protein. The cassette also included NeoR 
sequences flanked by FRT recombination sites. This modified 
SexAI fragment was then exchanged with its wild-type cog-
nate on the Sad clone. Finally the diptheria toxin A gene 
(DT-A) was added adjacent to the 5' Pnmt flank for negative 
selection. 
Forty-five micrograms of linearized vector DNA were 
electroporated into Rl mouse embryonic stem cells. G418-
resistant clones were isolated and their DNAs characterized 
22 
30 minutes each and then incubated in PBS containing 
mg/ml XGAL (5-bromo-4-chloro-3-indoyl-beta-Dpyrano-
side ), 5 mM ferricyanide, 5 mM ferrocyanide, 2 mM MgCl2 , 
and 0.2% Ipegal CA-630 (Sigma). After 15 hours at 
5 30.degree. C., the embryos were rinsed in PBS containing 3% 
DMSO and then stored at 4.degree. C. in PBS. 
D) Immunofluorescent Histochemical Staining 
Co-immunofluorescent histochemical staining was per-
formed essentially as described previously (Ebert and 
10 Thompson, 2001, supra). Primary antibodies used in this 
study include rabbit polyclonal antibodies from Chemicon 
International (Temecula, Calif.) that selectively recognize 
either Pnmt (ABllO) or HCN4 (AB5808), and mouse mono-
15 clonal antibodies from Sigma-Aldrich (St. Louis, Mo.) that 
selectively recognize either Th (T1299) or sarcomeric a-ac-
tinin (A 7811 ). Fluorescently-tagged secondary antibodies 
were obtained from Jackson Immunolabs (Denver, Pa.), and 
include fluorescein isothiocyanate (FITC)-conjugated don-
20 key anti-rabbit IgG and Texas Red-conjugated donkey anti-
mouse IgG. All antibodies were used at 1: 100 dilution, except 
for the anti-HCN4 antibody, which was used at 1:50 dilution. 
Embryos were isolated from timed-pregnant females and 
fixed with freshly prepared 4% paraformaldehyde in 0.1 M 
25 phosphate buffered saline, pH 7.3 for 1-2 hours on ice. The 
samples were then transferred to 30% sucrose solution in 
PBS, pH 7 .3, and allowed to equilibrate at 4.degree. C. for at 
least 48 hours. The sucrose-saturated samples were then 
shipped to FD Neurotechnologies, Inc. (Catonsville, Md.) for 
by Southern blotting using probes external to the targeting 
vector (FIG. 1). Cells from two positive clones were injected 
into C57BL/6 blastocysts and chimeric mice from these 
injections were mated to C57BL/6 females. Genotypes at the 
Pnmt locus were identified by PCR analysis using the follow-
ing primers: Primer 21 (5'-CAGGCGCCTCATCCCTCAG-
CAGCC-3', SEQ ID NO: 1); Primer 22 (5'-CTGGC-
CAGCGTCGGAGTCAGGGTC-3', SEQ ID NO: 2); and 35 
Primer 23 (5'-GGTGTACGGTCAGTAAATTGGACAC-
CGTCCTC-3', SEQ ID NO: 3). These amplification reactions 
yield products of 200 and of 160 bp for the wild-type and the 
mutant alleles, respectively. Pnmtcrei+ mice were then inter-
crossed or mated to R26R reporter mice as described in the 
text. 
30 sectioning (20 µm) and mounting onto SuperFrost Plus 
microscope slides (Fisher Scientific, Inc., Pittsburgh, Pa.). 
The sections were then frozen and stored at -SO.degree. C. for 
subsequent use. 
To perform the immunostaining procedure, the slides were 
first thawed at room temperature, and each section was ringed 
with a PAP pen (Research Products International, Mount 
Prospect, Ill.) to form an incubation well. The tissues were 
then rehydrated with PBS for 20 minutes, followed by incu-
40 bation with blocking solution (0.3% Triton X-100, 5% pow-
dered nonfat dry milk, and 0.02% sodium azide in PBS) for 
20-30 minutes at room temperature. The blocking solution 
was then replaced with fresh blocking solution containing the 
primary antibody (for co-staining, two different primary anti-
B) Catecholamine Radioimmuno-Assays 
Epinephrine and norepinephrine concentrations were mea-
sured by radioimmunoassay as described previously (Ebert 
and Thompson, 2001, supra). Briefly, adrenal glands were 
isolated from decapitated neonates and immediately frozen 
on dry ice. Individual adrenal gland extracts were prepared by 
sonication for 10 sec in 0.1 M HCI, followed by microcen-
trifugation (14,000xg, 10 min) to remove residual debris. The 
extracts were assayed using a commercially available radio-
immunoassay (ALPCO Labs, Inc., Wyndham, N.H.), and 
protein concentrations were determined using the Bio-Rad 
(Hercules, Calif.) protein assay. Equivalent amounts of pro-
tein (5 ng/sample) were assayed in a volume of 0.25 mis. 
Results are expressed as Mean.+-.S.E.M. and compared for 
statistically significant differences by one-way analysis of 
variance (ANOVA) with p<0.05 required to reject the null 
hypothesis. 
C) Whole-Mount Staining for ~-Galactosidase Activity 
Embryos were staged by timed matings. Females carrying 
a vaginal plug were removed from the mating cage and noon 
of that day was considered to be E0.5. Isolated embryos were 
fixed 50 minutes at 4.degree. C. in PBS containing 2% 
paraformaldehyde (w/v) and 2% glutaraldehyde (v/v). 
Embryos were rinsed at 4.degree. C. with PBS three times for 
45 bodies were included in the same incubation solution). Pri-
mary antibody incubations proceeded for one hour at room 
temperature and then overnight at 4.degree. C. in a humidified 
chamber. Following this incubation period, the primary anti-
body solutions were removed and the sections washed three 
50 times (10 minutes each) in PBS at room temperature. All 
remaining steps were performed at room temperature. Fluo-
rescently-tagged secondary antibodies were incubated with 
the sections for 2 hours at room temperature in the dark. The 
55 
secondary antibody solutions were then discarded and the 
sections washed in three successive changes of PBS. Slides/ 
coverslips were mounted with VectaShieldmounting medium 
(Vector Laboratories, Burlingame, Calif.). 
For experiments where XGAL staining and immunofluo-
60 rescent labeling were combined, Applicant first performed 
the XGAL staining on the sections overnight as described 
above. The XGAL solution was then removed, and the sec-
tions were washed with PBS (3xl 0-mins each) prior to initi-
ating the immunofluorescent staining as described in the pre-
65 ceding paragraph. Digital images were collected using a 
Nikon Eclipse El 000 fluorescence microscope, and pro-
cessed for display using Adobe Photoshop 5 .5 software. 
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Example 2 
Roles of Catecholamines in Cardiac Development 
The goal of this Example is to understand how catechola-
mines influence heart development. Genetic studies have 
shown that catecholamines are essential for proper embry-
onic development because mice lacking the ability to produce 
noradrenaline ( norepinephrine) and adrenaline (epinephrine) 
die from apparent cardiovascular failure in utero (Thomas et 
al., 1995, supra). The specific function of catecholamines in 
cardiac development, however, has not been elucidated. 
Applicant's research has shown that the heart itselfis a source 
24 
(from Chemicon International, Inc., Temecula, Calif.) in this 
assay to determine if it can serve as a useful marker for this 
experiment. HCNl is known to be expressed in the develop-
ing heart (Shi et al., 1999, Circ Res 85:el-e6), presumably in 
pacemaker cells (Mangoni et al., 2001, Cardiovasc Res 
52:51-64). The existing markers likely provide informative 
results regarding coexpression of catecholamine biosynthetic 
enzymes and pacemaker proteins. 
Another experiment is to evaluate Pnmt-GFP knock-in 
10 expression in the developing mouse heart. The objective is to 
determine if expression of GFP faithfully reproduces the 
pattern of the endogenous Pnmt gene. The rationale is that 
GFP expression should recapitulate PNMT expression since 
Applicant has inserted the GFP reporter gene into the mouse 
of epinephrine production at early stages of development 
(Ebert et al., 1996, supra), and that epinephrine-producing 
cells are transiently clustered in pacemaking and conduction 
centers (SA node, AV node, His bundle, ventricular septum) 
(Ebert and Thompson, 2001, supra). These findings have 
prompted applicant to propose that catecholamines are essen-
tial for cardiovascular development because they stimulate 
pacemaking activity and facilitate the differentiation of con- 20 
duction tissue. Three specific aims are described as follows: 
15 Pnmt locus.Applicant expects to find GFP-expressing cells in 
the embryonic mouse heart clustered around pacemaking and 
conduction centers. It is likely that GFP expression in these 
mice aids to identify, isolate, and characterize living cardiac 
adrenergic cells as described above. 
To obtain embryos that are heterozygous forthe Pnmt-GFP 
allele, homozygous Pnmt-GFP males are mated with wild-
type females. The embryos are isolated at various embryonic 
stages, fixed, processed, and sectioned for immunohis-
tochemical staining experiments. Initially, Applicant exam-
Specific aim 1 is to identify and characterize adrenergic 
cells in the embryonic mouse heart. This aim is to test the 
hypothesis that catecholamine-producing cells are pace-
maker cells in the embryonic mouse heart. The following 
experiments are carried out. 
One experiment is to perform co-immunofluorescent stain-
ing for adrenergic and pacemaker markers. The objective is to 
determine if catecholamine biosynthetic enzymes (i.e., 
PNMT, DBH, and TH) are expressed in pacemaker cells in the 
embryonic mouse heart. The rationale is that, if adrenergic 
cells are pacemaker cells, then Applicant should expect to 
find them in pacemaker regions of the developing mouse 
heart, as Applicant has seen in the embryonic rat heart. Fur-
ther, pacemaking proteins (e.g., HCN1&4 channel proteins) 
and catecholamine biosynthetic enzymes (PNMT, DBH, and 
TH) would be expected to be co-expressed in the same cells. 
Applicant utilizes dual immunofluorescent histochemical 
staining techniques to study the temporal and spatial expres-
sion patterns of catecholamine biosynthetic enzymes and 
pacemaker proteins in the developing mouse heart. The stain-
ing is performed essentially as described in Example 1. 
Embryos are isolated from timed-pregnant wild-type mice at 
E7.5, ES.5, E9.5, El0.5, E12.5, E14.5, and E18.5, and pro-
cessed for immunofluorescent histochemical staining. An 
outline of the co-staining strategy is depicted in Table 2. 
TABLE-US-00002 TABLE 2 Co-immunofluorescent his-
tochemical staining strategy outline. Primary antibody pairs 
Secondary antibodies Rabbit anti-PNMT+Mouse anti-TH+ 
FITC-conjugated Donkey Mouse anti-a-actinin*anti-rabbit 
IgG+ Texas Red-conjugated Donkey anti-mouse IgG Rabbit 
anti-DBH+Mouse anti-TH+Same as above Mouse anti-a-
actinin*Rabbit anti-HCN4+Mouse anti-TH+Same as above 
Mouse anti-a-actinin* Rabbit anti-HCNl+Mouse anti-TH+ 
Same as above Mouse anti-a-actinin* *Adjacent serial sec-
tions are co-stained for the myocyte marker, a-actinin, and 
the indicated rabbit antibody. 
25 ines them for expression of GFP using laser-scanning confo-
cal fluorescence microscopy. If GFP expression patterns are 
reflective of those that Applicant has observed for endog-
enous PNMT in the developing heart, then Applicant initiates 
co-staining experiments to help verify that GFP expression is 
30 confined to Pnmt-expressing cells. To accomplish this, Appli-
cant uses a rabbit anti-PNMT primary antibody with a Texas 
Red-conjugated anti-rabbit secondary antibody. Thus, this 
strategy should allow Applicant to visualize PNMT in the red 
spectrum and GFP in the green spectrum. Applicant can then 
35 overlay the images obtained from each wavelength separately 
to evaluate the degree of overlapping expression. 
Another experiment is to isolate and carry out electro-
physiological characterization of cardiac adrenergic cells. 
The objective of this experiment is to characterize the elec-
40 trophysiological properties of cardiac adrenergic cells. The 
rationale is that, if adrenergic cells are also pacemaker cells, 
then Applicant should expect to find spontaneous action 
potential generation similar to that observed in SA-nodal 
cells. In addition, pacemaker currents should be expressed in 
45 these cells, while inward rectifiers (e.g., IKZ) are not expected 
to be found in these cells (Mangoni et al., 2001, supra). 
Cells are isolated from Pnmt-GFP embryonic mouse 
hearts, and seeded onto collagen-coated glass coverslips for 
analyses using whole-cell patch-clamp recording techniques. 
50 Applicant patches the fluorescent cells from the mixed popu-
lation of GFP+ and GFP- heart cells seeded onto the cover-
slips. Applicant utilizes established protocols to measure 
action potentials, pacemaker (IF) and other cardiac ion cur-
rents Clea' L, lea' T, INa' etc.). If GFP-expressing cells are 
55 difficult to find, applicant can selectively enrich for them 
using fluorescence-activating cell-sorting (FACS) strategies. 
Alternatively, applicant uses the Pnmt-Cre/LacZ mice. In 
general, the Pnmt-Cre/LacZ mice can serve as a back-up 
model for essentially all of the experiments that Applicant is 
As shown in FIG. 9, the anti-HCN4 antibody selectively 
identifies presumptive SA nodal cells in the embryonic mouse 
heart. The specificity of the anti catecholamine biosynthetic 
enzyme antibodies (TH, DBH, and PNMT) has already been 
described (see Ebert & Thompson, 2001, supra). In addition, 
the use of an antisarcomeric a-actinin antibody as a marker 
for working myocardial cells is well-established. Thus, using 
these selective marker antibodies, Applicant determines if 65 
catecholamine biosynthetic enzymes are expressed in SA 
nodal cells. Applicant also tests a new anti-HCNl antibody 
60 proposing with the Pnmt-GFP mice. It is possible, for 
example, to isolate living Lacz+ cells by pre-incubating them 
with a fluorescent substrate, fluorescein dl-~-galactoside 
(FDG) and then using FACS to isolate the Lacz+ cells (Fier-
ing et al., 1991, Cytometry 12:291-301). 
Another experiment is to perform gene expression 
profile(s) of cardiac adrenergic cells. The objective is to iden-
tify genes uniquely expressed in cardiac adrenergic cells. The 
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rationale is that Applicant's hypothesis predicts that cardiac 
adrenergic cells become pacemaker/conduction system myo-
cytes. Applicant expects to find gene expression signatures 
for pacemaker (HCN) and other cardiac ion charmel proteins 
(e.g., subunits of charmels responsible for gating Ifl IN a' lea' 
L, lea' T, and I Kr-all of which have recently been shown to 
be present in mouse SA nodal cells) (Mangoni et al., 2001, 
supra). The results of this experiment can identify genes that 
are uniquely or preferentially expressed in ICA cells, poten-
tially providing novel information about how these cells 10 
develop and function. 
26 
results obtained with these mice, but Applicant has not seen 
any evidence for Lacz localization in Purkinje fibers. If an 
association with the proximal pacemaking/conduction cen-
ters is maintained in the mice, then Lacz expression in Pnmt-
Cre/R26R mice could represent a molecular marker that may 
be used to distinguish between proximal and distal compo-
nents of the pacemaking/conduction system in the developing 
heart. Alternatively, Applicant may find that adrenergic cells 
and their descendents (Pnmt-Cre/LacZ+) are simply in the 
vicinity of developing pacemaking/conduction centers at cer-
tain stages of development, but that they are not actually the 
pacemaking/conduction myocytes themselves. This issue 
should be clarified by successfully completing the following 
GFP+ cells are isolated from El0.5 Pnmt-GFP knock-in 
mouse hearts by enzymatic/mechanical dissociation of 
embryonic hearts into single cells (Maltsev et al., 1994, Circ. 
Res. 7 5 :233-244) that are separated into GFP+ and GFP- cell 
populations using FACS. RNAs are purified from the isolated 
cells and analyzed usingAffymetrix mouse expression chips. 
Expression patterns for cardiac adrenergic cells (GFP+) are 
compared to non-adrenergic cardiac cells (GFP-). 
15 
co-immunofluorescent staining experiment. 
Another experiment is to perform co-immunofluorescent 
histological staining to identify specific cell types. The objec-
tive is to identify the specific cardiac cell type( s) that produce 
catecholamines in the developing heart. The rationale is that 
Applicant has recently performed a pilot gene chip screen 
using RNA isolated from neonatal rat cardiomyocytes that 
had been cultured for 10 days in the absence and presence of 
adrenergic receptor blockers (timolol and phenoxyben-
zamine, 10 µMeach). The samples were analyzed using the 
Affymetrix Rat Genome U34A GeneChip®, containing 8799 
gene fragments that represent all full-length or armotated 
genes. Interestingly, connexin 43 expression was decreased 
20 ifapplicant' s hypothesis is correct, then developing SA nodal 
cells should be Lacz+ in embryos from Pnmt-CrexR26R 
matings. Applicant's preliminary data suggest that ICA cells 
are found in pacemaking/conduction system tissue as well as 
in other parts of the heart. The results from the proposed 
25 experiments should provide cell type-specific identification 
of cells that are ICA descendents. This information is poten-
tially important because it is likely to provide novel insight 
about fundamental aspects of cardiac development and func-
tion. 
by -65% following adrenergic receptor blockade. Cx43 is 
mentioned only because Applicant has other corroborating 
data indicating that its expression may be positively influ- 30 
enced by the presence of catecholamines (FIGS. 9-10). Any 
interesting leads are pursued by first replicating the experi-
mental results, and then using independent, conventional 
assays such as Northern and Western blots, to confirm (or 
refute) the gene-chip data (for selected genes). 
Applicant performs dual immunofluorescent histochemi-
cal staining for ~-gal and various cell type-specific markers. 
Applicant first verifies that ~-gal expression occurs in ICA 
cells by co-staining embryonic sections with anti-~-gal and 
anti-catecholamine biosynthetic enzyme antibodies. To iden-
Specific aim 2 is to map the fate of cardiac adrenergic cells 
in the developing mouse heart. This aim is to test the hypoth-
esis that catecholamine-producing cells are the progenitors of 
cardiac pacemaking and conduction system myocytes in the 
mouse. The following experiments are carried out. 
35 tify specific cell types, Applicant proposes to use the antibod-
ies listed in Table 3 below. 
TABLE-US-00003 TABLE 3 A list of cell type specific anti-
bodies. Cell Type Target Antigens Antibody Source Intrinsic 
Cardiac PNMT Rabbit anti-PNMT Ebert Adrenergic (ICA) 
One experiment is to localize Pnmt-Cre/LacZ expression 
40 cells TH Mouse anti-TH Sigma ICA+Descendents ~gal 
Mouse anti-~gal Sigma ICA+Descendents ~gal Rabbit anti-
~gal Chemicon or Hoechst Cardiomyocyte Sarcomeric a-ac-
tinin Mouse anti-a-actinin Sigma Pacemaker cells HCN4 
in developing mouse heart. The objective is to identify and 
map the fate of adrenergic cells in the developing mouse 
heart. The rationale is that, if adrenergic cells contribute to the 
development of the pacemaking/conduction system of the 45 
heart, then Applicant might expect to find them preferentially 
localized to regions of the heart that give rise to the SA-node, 
AV-node, Bundle of His, and Purkinje fibers. 
Applicant crosses Pnmt-Cre mice with R26R mice to cre-
ate embryos that express Lacz only in Pnmt-expressing cells. 50 
For early embryonic stages (E7 .5-E12.5), whole-mount ~-ga­
lactosidase staining is performed. Positive staining is 
intensely blue. Staining patterns are documented using digital 
photomicroscopy. The stained embryos are then be sectioned, 
counterstained with eosin, and re-photographed at low and 55 
high magnification. Because of diffusion concerns in the 
larger later stage embryos (E13 and later), whole-mount 
staining is not performed with them. Instead, isolated 
embryos or tissues (e.g., heart, adrenal glands) are first fixed 
and sectioned prior to staining for ~-galactosidase. Staining 60 
patterns are compared with published histological and ana-
tomical evaluations of mouse cardiac development. 
It is clear that Lacz expression in Pnmt-Cre/R26R 
embryos is not restricted exclusively to pacemaking and con-
duction centers. The proximal components of the pacemak- 65 
ing/conduction system-i.e., SA node, AV node, and bundle 
of His regions appear to be included in the ~-gal staining 
pacemaker Rabbit anti-HCN4 Chemicon channel Conduc-
tion cells* Connexins (Cx43, Mouse anti-Cx43 Sigma Cx40, 
and Cx45) Rabbit anti-Cx40 & Cx45 Thompson Neural crest 
cellsAP-2transcript. factor Rabbit anti-AP-2 Santa Cruz Bio-
tech Proepicardial and a4-Integrin Mouse anti-a4 integrin 
Chemicon neural Rabbit anti-a4 integrin crest cells Endot-
helial cells PECAM Rat anti-PECAM Pharmingen Smooth 
muscle cells a-sm. muscle actin Mouse anti-aSMA Sigma 
*Conduction cells are actually a heterogeneouos collection of 
cells that express various gap junction proteins (connexins). 
Each connexin is expressed in a specific non-uniform pattern 
in the developing heart. Cx43 is most widespread, while Cx40 
becomes largely restricted to atrial tissue, and Cx45 is most 
prevalent in pacemaking and conduction nodes. 
Another experiment is to examine proliferative activity of 
cardiac adrenergic cells. The objective is to determine if car-
diac adrenergic cells proliferate in the developing mouse 
heart. The rationale is that terminally differentiated cardi-
omyocytes are thought to be largely post-mitotic. Applicant 
anticipates that cardiac adrenergic cells may represent a tran-
sient cardiac phenotype, and they ultimately differentiate into 
pacemaking and conduction system myocytes. As such, 
Applicant finds that unlike mature cardiomyocytes, cardiac 
adrenergic cells still retain proliferative capabilities. 
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Applicant uses the bromodeoxyuridine (BrdU) labeling 
strategy for labeling DNA-synthesizing cells in the develop-
ing heart (see, e.g., Cheng et al., 1999, Development 126: 
5041-5049). Each animal will receive two IP injections of 
bromodeoxyuridine (160 mg BrdU/kilogram body weight) 
two hours apart, followed by euthanasia and sacrifice four 
hours after initial injection, for a total labeling period of 4 
hours. Hearts will be immediately removed, flushed with 
heparinized saline for retrograde aortic perfusion, and fixed 
by perfusion with methanol/DMSO (80/20). Formaldehyde 
fixation, as needed for other antibody staining, will require 
retrieval of BrdU antigenicity with 2N HCl, now routine. 
Alternatively, if two or three channel immunofluorescence of 
other markers would be useful, DNA-replicating cells may be 
labeled with 3H-5-methyl-thymidine (IP) for autoradio-
graphic colocalization with fluorescent markers (see, e.g., 
Sedmera et al., 2002, Anat Rec 267:137-145). 
28 
ranted by results from the earlier experiments and/or relevant 
reports published by other groups. 
The Dbh knockout mouse model originally described by 
Thomas et al. (1995, supra) are used for this experiment. 
Although Dbh-1- embryos die of cardiovascular failure in 
utero, they can be rescued by administration ofDOPS in the 
maternal drinking water (note that DOPS can be converted to 
NE in vivo by an alternative pathway). After birth, DOPS is no 
longer needed for survival or reproduction, so it is completely 
10 feasible to generate Dbh_;_ dams for this experiment (see 
FIG. 9). The Dbh gene, not the Pnmt or Th genes, is the key 
knockout target for this experiment. As describe above, 
homozygous disruption of Pnmt resulted in loss of EPI pro-
duction in the developing mouse, but this did not result in any 
15 observed lethality or overt phenotype. Thus, EPI is not essen-
tial for cardiovascular development (provided that NE is 
present). On the other hand, loss ofEPI and NE is an embry-
onic lethal phenotype, with Dbh_;_ mice dying between Another experiment is to examine migration capability of 
cardiac adrenergic cells. The objective is to determine if car-
diac adrenergic cells migrate. The rationale is that data from 20 
the immunofluorescent and ~-gal staining experiments indi-
cate that cardiac adrenergic cells may arise from proepicar-
dium and neural crest, two highly migratory cell types (see 
e.g., Li et al., 2002, Development 129:2031-2042; Maschhoff 
and Baldwin, 2000, Am J Med Genet. 97:280-288). Migra-
tion of cardiac adrenergic cells is likely to be detected. 
El0.5 and E13.5 (Thomas et al., 1995, supra). 
Applicant already has Dbh_;_ mice and is establishing a 
small breeding colony of these animals for use in this and 
subsequent experiments. One alternative strategy would be to 
selectively eliminate NE/EPI production from cardiac cells 
using a cardiac-specific Cre-recombinase gene that is 
25 expressed at early stages of cardiac development in adrener-
gic cells. 
Proepicardial and branchial arch regions of the Pnmt-GFP 
embryos are isolated at E9.5-E10.5 and explanted onto col-
lagen-coated coverslips, cultured and assayed as described by 
Li et al., 2002, supra). Fluorescent (e.g., GFP-expressing) 
cells are recorded using fluorescence-based time-lapse video 
microscopy. Similar assays are performed with enzymati-
cally-dissociated cells isolated from Pnmt-GFP mouse hearts 
between E8.5 and El 1.5. In both assays, Applicant calculates 
the distance traveled and speed of migration. Fluorescent 
beads are included in the cultures to provide fixed reference 
points. 
Specific aim 3 is to evaluate the development of pacemak-
ing/conduction tissue function in the absence and presence of 
norepinephrine and epinephrine. This aim is to test the 
hypothesis that norepinephrine and/or epinephrine are 
required for functional development of the cardiac pacemak-
ing/conduction system. The following experiments are car-
ried out. 
One experiment is to examine pacemaker/conduction 
marker expression.+-.catecholamines. The objective is to 
determine ifthe expression of pacemaker (HCN4) and con-
duction (Cx43) system markers is altered in the absence of 
endogenous catecholamines (Dbh-1- mice) relative to their 
expression in catecholamine-competent (Dbh+/+ or Dbh+1-) 
embryos. The rationale is that, ifNE and/or EPI are necessary 
for pacemaker/conduction system development, then Appli-
cant expects to find altered expression patterns for HCN4, 
Cx43, and/or additional pacemaker/conduction system mark-
ers in catecholamine-deficient hearts. 
Applicant compares the expression patterns of HCN 4 and 
Cx43 in catecholamine-deficient (Dbh_1_) and normal 
embryos (Dbh+1-) obtained from parental crosses of Dbh+1-
malexDbh-1- female (to preclude rescue of embryonic lethal-
ity by maternal sources of NE/EPI). Development of het-
erozygous (Dbh+1-) embryos appears completely normal 
with no associated embryonic lethality. Thus, Applicant com-
pares HCN4 and Cx43 expression in Dbh-1- and Dbh+1-
embryos from the same litters between E8.5 and El0.5, the 
developmental period immediately preceding the onset of 
lethality in Dbh-1- embryos. This strategy can be expanded to 
include other markers as they become available and as war-
Another experiment is to evaluate pacemaker activity.+-
.catecholamines. The objective is to determine if intrinsic 
pacemaking activity is altered by the absence of endogenous 
30 catecholamines, beating rates are measured from wild-type 
and catecholamine deficient embryonic hearts under physi-
ologic conditions. Receptor-specific adrenergic drugs are 
employed to help identify the subtype( s) of adrenergic recep-
tors involved in mediating these responses. The rationale is 
35 that, if endogenous catecholamines stimulate pacemaking 
activity, thenApplicant should find that Dbh_;_ embryos have 
slower heart rates than their wild-type siblings. This has 
already been demonstrated to some extent, though the mea-
surements were performed at room temperature rather than at 
40 37.degree. C. Applicant plans to extend these initial findings 
by carefully comparing rates at 37.degree. C. in the absence 
and presence of various adrenergic drugs. NE/EPI or ~-ago­
nists should rescue/recover rates. Alpha-adrenergic drugs 
may also show some activity. Conversely, beating rates in 
45 wild-type embryos may be sensitive to adrenergic receptor 
blockade. Catecholamines can act acutely on pacemaker cells 
since their absence (Dbh-1- mice) did not appear to alter 
pacemaker channel expression. Hence, the cellular pace-
maker "machinery" appears to be in place, but it still may 
50 need some external stimulation by NE/EPI to operate effi-
ciently (e.g., to sufficiently maintain cardiac output at early 
pre-innervation stages of development). 
Applicant sets up matings between Dbh_;_ females and 
Dbh+1- males to generate offspring that are -50% Dbh-1-
55 (embryonic lethal between E10.5-E13.5) and -50% Dbh+/-
(indistinguishable from wildtype ). The embryos are isolated 
at El0.5 and placed in pre warmed, oxygenated, serum-free 
culture media (DMEM) for assessment of beating rates in an 
incubation chamber equipped with an inverted phase-contrast 
60 microscope with an attached video camera. The embryos are 
equilibrated in the culture media under physiological condi-
tions for at least 20-30 mins prior to performing beating rate 
assessments. Photodiode sensors positioned on the video 
screen detect light changes that occur as result of cardiac 
65 contractions, and these signals are converted to electrical 
signals that are acquired and analyzed using National Instru-
ments' data acquisition hardware and software (customized 
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Lab View 4.0 software). Beating rates are recorded from one 
embryo at time, and Applicant first obtains a baseline rate 
before evaluating drug effects. The baseline rate is recorded 
over 5-10 mins. prior to the addition of indicated drug, as 
outlined in Table 4 below. The drugs are evaluated over a 5 
broadrange of concentrations (e.g., 0, 0.01, 0.1, and 1 µM) by 
progressively increasing the amounts of drug administered to 
each sample. 
TABLE-US-00004 TABLE 4 Outline of drug-testing strategy 
for beating rate assessments. Drug Receptor Specificity 10 
Genotype to be tested Epinephrine Nonselective agonist 
Dbh-1- Norepinephrine Semi-selective agonist Db!P- (poor 
~2 agonist Isoproterenol Nonselective ~ agonist Dbhl- Terb-
utaline Selective ~2 agonist Dbh-1- Phenylephrine Selective 
30 
dye, and both spontaneous and stimulated electrical activity 
were recorded using a photodiode array (FIG. 12). In this 
initial experiment, Applicant estimated the conduction veloc-
ity to be -0.16 mm/msec. The data showed that the signal-to-
noise ratio is very large(> 10), indicating that the technique is 
capable of measuring the propagating velocity on a small 
spatial scale (-20 µm). 
Another experiment is to carry out cap junction assays.+-
.catecholamines. The objective is to determine if gap junction 
development is impaired in embryonic hearts from catechola-
mine-deficient mice. The rationale is that Applicant's pre-
liminary studies suggest that gap junction (Cx43) expression 
is impaired in Dbh_;_ embryos. Gap junction deficiency could 
compromise the ability of the developing heart to effectively 
transmit electrical signals through the myocardium, resulting 
in poor conduction and coordination of electrical activity in 
the heart. There is also some pharmacological evidence sug-
gesting that gap junction activity can be regulated through 
adrenergic signaling pathways (for review, see Dhein, 1998). 
a 1 agonist Dbh_;_ Timolol Nonselective ~ Wild-type and 15 
antagonist heterozygotes (Dbh+1-) Atenolol Selection ~ 1 
antagonist Wild-type and heterozygotes (Dbh+1-) Phenoxy-
benzamine Nonselective a Wild-type and antagonist het-
erozygotes (Dbh+1-) Prazosin Selective a 1 antagonist Wild-
type and heterozygotes (Dbh+1-) 
Another experiment is to identify regional action potential 
(AP) characteristics (conventional microelectrode). The 
objective is to determine if the absence of endogenous cat-
echolamines alters the generation and/or propagation of elec-
trical signaling in the heart. The rationale is that different 25 
regions of the developing heart have characteristic types of 
action potentials associated with them. If endogenous cat-
echolamines are required to stimulate and help to coordinate 
electrical signaling activity in the developing heart, then 
altered action potential profiles in catecholamine-deficient 30 
embryos can be detected. 
20 If Applicant can show that gap junction activity is signifi-
cantly decreased in Dbh-1- embryonic hearts relative to 
Dbh+/- or Dbh+/+ hearts, then such a result would strongly 
support the data showing that Cx43 expression is reduced in 
Dbh_;_ and Dbh+/- embryos are isolated at El0.5, decapi-
tated, and placed in a pre-warmed, oxygenated incubation 
chamber. Using conventional microelectrode recording tech-
niques, Applicant records transmembrane voltages from 35 
three regions-atrial, ventricular, and outflow tract. Appli-
cant compares the upstroke velocity, duration, and shape of 
the action potentials recorded from these specific cardiac 
regions. As an initial test of the feasibility of this approach, 
Applicant isolated E12.5 rat embryos and recorded action 40 
potentials from different regions of the heart, as shown in 
FIG. 11. These results, represented by the action potential 
traces drawn outside the boxed regions in FIG.11, are similar 
embryos deprived ofNE/EPI. 
Applicant uses a variation of the fluorescent dye-coupling 
assays described by Li et al. (2002, supra) andAi et al. (2000, 
J Clin Invest 105: 161-171) to evaluate gap junction function. 
Cardiomyocytes are isolated from Dbh-1- and Dbh+1- mouse 
embryos at E9.5-E10.5, cultured at various densities for 24 
hours on collagen-coated glass coverslips, and subjected to 
the dye-coupling assay. This involves loading fluorescent dye 
intracellularly via a patch pipette and subsequently counting 
the number of coupled cells obtained as a result of this treat-
ment (defined as those that become obviously fluorescent 
after dye injection). 
Another experiment is to perform gene expression profil-
ing using gene chip microarray analysis. The objective is to 
determine if genes encoding for gap junction and other con-
duction cell proteins are influenced by catecholamines. The 
rationale is that, if catecholamines influence differentiation of 
conduction tissue, then Applicant may expect to see altered 
patterns of conduction system markers in catecholamine-
deficient hearts. RNAs are isolated from Dbh_;_ and Dbh+/-
to those published previously (shown inside the boxes with sibling hearts at El0.5, and used for microarray analysis. This 
corresponding heart diagrams for each age). 45 strategy can evaluate how the absence vs. the presence of 
Another experiment is to perform optical mapping of endogenous catecholamines affects gene expression in the 
action potentials using photodiode array detection. The heart. The expression of specific genes as well as patterns of 
objective is to measure conduction velocity in the absence gene expression (cluster analysis) can be evaluated essen-
and presence of endogenous catecholamines. The rationale is tially as described above. 
that rapid and directed propagation of electrical signals 50 Specific Methods 
through the myocardium is critical for the development and Double immunofluorescent histochemical stammg and 
maintenance of cardiac performance. If catecholamines are whole-mount ~-galactosidase staining is performed as 
required to stimulate the development of the conduction sys- described above in Example 1. 
tern, then Applicant might expect to find significantly slower Isolation of embryonic cardiac cells is performed as 
conduction velocities and altered vector directions in cat- 55 described by Maltsev et al. (1999). Briefly, embryonic hearts 
echolamine-deficient embryos. are isolated by surgical dissection and pooled in Hank's Bal-
To evaluate propagation of the conduction signal through anced Salt Solution (Ca++/Mg++_free) on ice. The tissue is 
the developing heart, Applicant uses voltage-sensitive dyes then be pre-warmed to 37.degree. C., and transferred to pre-
and optical (photodiode arrays) imaging techniques to simul- warmed collagenase buffer containing 1 mg/ml collagenase B 
taneously record action potentials from many locations and 60 (Roche) and the following (in mM): NaCl (120), KC! (5.4), 
map the direction of conduction in the heart as has been MgS04 *7H20 (5), Pyruvic acid (5), Taurin (20), Hepes (10), 
elegantly described in Rentschler et al., 2001, Development Glucose (20), and CaCl2 (0.03), pH 6.9. Digestion proceed at 
128: 1785-1792; Rentschler et al., 2002, Proc Natl Acad Sci 37.degree. C. with intermittent swirling for 30 mins. Colla-
USA 99: 10464-10469). Applicant has performed some pre- genase digestion is terminated by the addition of KB buffer 
liminary tests of this experimental strategy using El0.5 65 consisting of (in mM): KC! (85), K2 HP04 (30), 
mouse hearts in short-term (1-5 hrs) culture. The hearts were MgS04 *7H20 (5), EDTA (1), Mg2 ATP (5), Pyruvic acid (5), 
stained with di4-ANEPPs, a fluorescent voltage-sensitive Creatine (5), Taurin (20), and Glucose (20), pH 7.2. The tissue 
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is mechanically dissociated by subjecting it to mild rocking 
for 30 mins. Final dissociation is achieved with mild tritura-
tion. Single cells are collected by passing the material through 
sterile 70 µm mesh filters to remove clumps and other debris. 
The cells can then either be seed onto collagen-coated cover- 5 
slips for whole-cell patch-clamp analysis, or then can be 
further separated into fluorescent and non-fluorescent cardiac 
cells using FACS. 
32 
tocurrent from the photodiode is about 100 pA. The optical 
signal size (dF/F) was about lx10-2 to 5x10-3 of the resting 
fluorescent intensity. Optical recording trials are usually 20 
seconds long, and 30-50 trials are recorded to limit the total 
exposure time to less than 100 seconds for each preparation. 
Signals from the photodiode array and two local field poten-
tial electrodes are digitized with a 12-bit data acquisition 
board (Micro star Laboratories, Bellevue, Wash.) installed in a 
PC. Before digitization, a 4-pole Bessel analog low-pass filter Action Potential Recordings can be performed as below: 
1) Conventional Microelectrodes 10 with a 333 Hz corner frequency is applied to all optical 
channels to ensure that the frequency of the analog signals 
was lower than the Ny quest frequency of the sampling. Digi-
tized data is directly transferred to the hard disk of the com-
Conventional microelectrodes having tip resistance in the 
range ofl 5-25 megaohms are pulled on a horizontal micropi-
pette puller (Model P-87, Sutter Instruments Co., Novato, 
Calif.) from TW120F glass (WPI, Sarasota, Fla.) and filled 
with 3 M KC!. Microelectrodes are coupled to an electrom- 15 
eter (model 750, WPI, Sarasota, Fla.) whose output is con-
nected to a conditioning amplifier (Meca, Indianapolis, Ind.) 
that allows both amplification and electronic derivation of 
voltage with respect to time. The dual voltage outputs of this 
recording amplifier are connected to an oscilloscope with 20 
dual sweep capability (Tektronix, model 5B12N) and an 
IBM-AT compatible Pentium II computer with a fast AID 
board and analysis software (APES, Hugo Sachs Elektronik, 
March-Hugsgetten, Germany). Applicant's analyses include 
measurement of the resting membrane potential, upstroke 25 
velocity, amplitude, and duration (APD50 andAPD90) of the 
action potentials recorded from analogous regions of wild-
type and Pnmt knockout embryonic mouse hearts. 
puter for subsequent analysis. 
Whole cell voltage-clamp recording-Voltage-clamp 
studies are performed essentially as described in the preprint 
article by Katchman et al. (JPET, 2002). The specific proto-
cols for individual current evaluations are provided below: 
1) IKrinwardly rectifying background K+ current-The 
inward-rectifier potassium current OKI) is elicited by com-
mand pulses (500 msec duration) from a holding potential 
-40 m V (to inactivate sodium channels) to between -100 m V 
and +40 m V at increments of 10 m V. The interval between 
pulses are 10 seconds. 
2) IK-delayed rectifier K+ currents OKs and IKr)-The fol-
lowing protocol is used to evaluate the slow component of the 
delayed-rectifier potassium current OKs). A 7 .5 sec test pulse 
is delivered from a holding potential of -40 m V to +40 m Vin 
10 m V increments in the presence of the selective I Kr blocker, 2) Optical Measurements with Voltage-Sensitive Dyes and 
Photodiode Array Detection 30 E4031 (1 µM), and tail currents are measured upon repolar-
ization to -40 m V. The rapid component of the delayed rec-
tifier, IK" is measured as the E4031-sensitive difference cur-
rent using the same protocol except that the duration of the 
Imaging with voltage-sensitive dye (VSD) provides sub-
millisecond temporal resolution for examining the synchro-
nization among heart tissue or cultured heart cells. In cultured 
cells, the sensitivity of the method permits resolution of 
single action potentials from individual neurons. Thus, the 35 
diversity in conductance and the shape of the action potential 
in the cell population can also be examined. Staining: Heart 
tissue slice or cultured dissociated cells are incubated for 30 
pulse is 1.5 seconds ratherthan 7.5 seconds. In both cases, the 
interval between pulses is 20 seconds. The I-V relationships 
for IK are constructed by measuring tail currents as previously 
described (Liu et al., 1998, J Pharmacol Exp Ther 285:672-
679; Liu et al., 1998, J Pharmacol Exp Ther 287:877-883). 
3) I;-hyperpolarization-activated (pacemaker) current-To 
40 evaluate Ifl Applicant uses a modification of the protocol 
described by Difrancesco et al. (J Physiol 1986, 377:61-88). 
Briefly, the holding membrane potential is clamped at -40 
m\7, and long (up to 1.5 seconds) hyperpolarizing pulses in 
increments of 10 m V are applied from holding potential level 
to 60 min in ringer solution containing 0.05 mg/ml of the 
voltage-sensitive dye Di4-ANEPPS (Molecular Probes, 
Eugene, Oreg.). The ringer is gently stirred and bubbled with 
carboxygen and kept at 27-32.degree. C. During this staining 
period, some dye molecules diffuse to the cell membrane and 
bind to the lipid bilayer. This dye does not penetrate into the 
cell. Although the staining is not selective to the cardiac 
muscle cells, only excitable membrane can generate signal 
(color change) and dye stained on the connective tissue only 
contributes to the background fluorescence. The stained 
preparation is perfused with a warm (34-37 .degree. C.), oxy-
genized Ringer on the stage of an upright microscope. The 
image of the cells is projected onto a photodiode array, and the 
dye molecules binding to the membrane convert the trans-
membrane potential change into the changes in fluorescence 
intensity. The photocurrent produced by the fluorescent light 
thus is linearly correlated to the trans-membrane potential of 55 
the cells. Optical imaging is performed with a 124-element 
photodiode array (Centronics Inc., Newbury Park, Calif.) at a 
frame rate of 1,000 frames/second. A 5x (NA. 0.12, Zeiss) 
objective is used to project the image of the preparation onto 
the array where each photodetector receives light from a 
0.33x0.33 mm2 area of the slice. The photocurrent of dye-
related fluorescent signals (at wavelength of 650 nm) from 
each photodetector are individually amplified through a two 
stage amplifier system. The amplifiers perform a current to 
voltage conversion using a feedback resistor of 1 G-ohm, and 
then a voltage gain of 1000, and a high-pass filter with a 
time-constant of 1 sec (0.16 Hz comer frequency). The pho-
45 up to -130 m V. Applicant considers If to be present in a given 
cell if Applicant observed a cesium-sensitive, time-dependent 
inward current. These observations are confirmed by block-
ing the current with the I_rspecific inhibitor, ZD7288. I-V 
relationship is obtained by plotting tail current amplitude 
50 versus the tail step potential. The steps (-70 to + 10 m V, in 
increments of 10 mV) are applied following the hyperpolar-
izing step to -120 mV to maximally activate If' Reversal 
potentials and current densities are evaluated as described 
above. 
4) !Na-fast inward sodium current-The voltage depen-
dence of activation ofINa is examined using -110 to -90 m V 
holding potentials. Test pulse of 25 msec duration is applied 
in increments of 10 mV from -100 to +80 mV. The steady-
state inactivation (availability) curves are constructed using a 
60 25 msec test pulse to -30 mV preceded by conditioning 
pulses from -120 to +20 mV (in 10 mV increments), and 
(Na+) are symmetrically set at 5 mM. In these experiments 
high TEA internal and external solutions are used. Calcium 
currents are blocked by using either nifedipine (1 µM) or 
65 100-200 µM Cd2 +, and low concentrations (200 µM) of Ca2 +. 
5) Ica,L-L-type calcium Ca2+ current-The L-type cal-
cium current is measured as described previously (Liu et al., 
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1998, J Pharmacol Exp Ther 287:877-883) by holding the 
membrane potential at -60 to -40 m V to inactivate the 
sodium current. In addition, TTX (10 µM) is used in some 
experiments where more negative voltages are required as 
holding potentials. To examine the voltage-dependence and 
kinetics oflca,L, 100-200 ms test pulses from -60 to +80 m V 
in 10 m V increments are applied. The kinetics of inactivation 
of this channel are analyzed quantitatively when either Ca2+ 
or Ba2+ are the charge carriers through the channel to deter-
mine both the Ca2 +-induced and voltage-mediated compo-
nents of the inactivation process. The voltage-dependence of 
steady-state inactivation (availability curves) is constructed 
using 500 ms conditioning pulses between -100 to +80 m V 
(given in 10 m V increments from a holding potential of -60 
m V) followed by a 100 ms test pulse to 0 m V. Recovery from 
inactivation and its voltage-dependence is also examined by 
varying the recovery interval between the test and condition-
ing pulses at different holding potentials. All solutions have 
high concentrations of Cs+ and TEA, but contain no Na+. 
Ica,L is studied both in the basal state (i.e., no added cAMP) 
and in the fully phosphorylated state (200 µM cAMP) of the 
channel. 
Example 3 
Molecular Imaging of Novel Cardiomyocyte Stem Cells 
The goal of this Example is to test the hypothesis that 
molecular and cellular imaging techniques identify, track, 
and functionally assess a novel population of cardiomyocyte 
stem cells for their potential to regenerate cardiac muscle 
tissue in vivo. A schematic illustration of cardiomyocyte dif-
ferentiation is shown in FIG. 13. 
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differentiate into cells other than myocytes in the heart. This 
experiment is important for determining the full potential of 
cardiac Pnmt+ cells in vivo. 
Applicant uses dual immunofluorescent and XGAL his-
tochemical staining techniques to identify and map the 
expression patterns of Pnmt+ cells and their descendents in 
fixed mouse heart sections. These experiments are performed 
largely as described above except that additional cell type-
specific antibodies are included to determine if Pnmt+ cells 
10 give rise to any non-myocyte cell types in the heart. A sum-
mary of the representative antibodies that are employed for 
this analysis is listed in Table 5. Additional cell type-specific 
antibodies are available for each of the cell types listed. The 
immunofluorescent staining analyses are performed in con-
15 junction with XGAL histochemical staining. Confocal laser-
scanning fluorescence microscopy is used in combination 
with bright-field microscopy to visualize cellular and sub-
cellular patterns of expression for these markers in the devel-
oping heart. 
20 TABLE-US-00005 TABLE 5 Examples of Cell Type-Spe-
cific Antibody Markers Available for Co-Staining Experi-
ments. Cell Type Antibody Marker Source References Stri-
ated Muscle Sarcomeric a-actinin* Sigma-Aldrich Ebert & 
(St. Louis, Mo.) Thompson, 2001 Smooth Muscle a-Smooth 
25 muscle actin Pacemaker Cells HCN4* Chemicon (SAN and 
AYN) (Temecula, Calif.) Intrinsic Cardiac PNMT* Chemi-
conAdrenergic (ICA) Cells (Temecula, Calif.) Cardiac Stem 
Cells c-Kit* Santa Cruz Biotech (Santa Cruz, Calif.) Epicar-
dial Cells a4-integrin Santa Cruz Biotech (Santa Cruz, Calif.) 
30 Endocardial Cells PECAM Cardiac neurons Choline Sigma-
Aldrich Acetyltransferase* (St. Louis, Mo.) (ChAT) Fibro-
blasts Prollagen I *Antibodies that Applicant has tested in 
published (Ebert & Thompson, 2001; Ferreira et al., 2001) 
and preliminary studies. Applicant's data indicate that cardiac cells transiently 
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expressing the enzyme, Pnmt, ultimately become myocytes 
Applicant focuses on three age groups for this experiment: 
(1) Neonatal (PO-P4); (2) Young Adult (8-10 wks); andAged 
(> 1.5 yrs). Applicant has already completed most of the pre-
natal analysis. Most of the work is done with neonates to 
make the most efficient use of time and resources. The struc-
that contribute substantially to pacemaking, conduction, and 
working myocardium. Thus, Pnmt serves as a novel marker of 
cardiomyocyte progenitor cells (Pnmt+ cells) in the develop-
ing heart. Applicant tests the idea that Pnmt+ cells can be 
selectively isolated and transplanted into damaged cardiac 
regions where they are monitored both physically (location) 
and physiologically (function) in vivo using non-invasive 
molecular and cellular imaging techniques. An exemplary 
method is shown in FIG. 14. Four specific aims are described 
as follows: 
40 ture of the neonatal heart is similar to that of adults, yet its 
smaller size means that less reagents (primarily antibodies) 
are needed to perform this experiment than would be used for 
adult sections. Applicant has already tested about one-half of 
the antibodies listed in Table 5 (see asterisks) in neonatal 
One aim is to determine the fate of Pnmt+ cells in the heart 
using newly developed mouse genetic models and "conven-
tional" cellular/molecular imaging techniques (immunofluo-
rescent histochemical staining and confocal laser-scanning 
fluorescence microscopy). This aim establishes the cellular 
anatomical distribution pattern of Pnmt+ cells and their 
descendents in developing mouse hearts. 
45 mouse hearts, but Applicant has not yet looked specifically at 
non-myocyte markers that may identify Pnmt descendents as 
neuronal, epicardial, endocardial, smooth muscle, or fibro-
blast cells. Once the staining is done in neonates, more limited 
testing in adults is performed to determine if the pattern of 
50 staining is fundamentally different from that observed in the 
One experiment is to determine the fate of Pnmt+ cells in 
the heart using Pnmt-CrexR26R mice. This experiment tests 55 
the hypothesis that cardiac Pnmt+ cells differentiate into myo-
cytes in vivo. Applicant has already made substantial progress 
in this area using the newly developed Pnmt-Cre mice. When 
bred with R26R reporter mice, Pnmt-Cre activated Lacz 
expression, thereby allowing Applicant to identify and map 60 
descendents of Pnmt+ cells in the developing mouse heart 
with XGAL staining. Applicant has examined embryonic, 
fetal, and neonatal hearts. Applicant also examines adult and 
aged hearts in similar fashion to determine if Lacz+ cells 
persist and maintain the patterns of distribution noted in the 65 
late fetal/early postnatal period. Further, Applicant uses addi-
tional cell type-specific markers to determine if Pnmt+ cells 
neonate. 
One aspect of adult hearts that is different from neonates is 
that the development of the intrinsic cardiac nervous system 
is still immature in neonates, but is fully developed in the 
adult. Applicant carefully examines Lacz expression in car-
diac neurons in adult hearts. As indicated from Table 5, Appli-
cant uses an anti-ChAT antibody as a marker for cholinergic 
neurons. Another neuronal marker that may be useful is an 
antibody that recognizes the a 3 subunit of the neuronal nico-
tinic receptor (a3 -nAChR). Another method that should 
prove useful here is silver staining, which selectively identi-
fies neurons. The silver staining technique is relatively inex-
pensive and easy to perform. It should be relatively straight-
forward to combine silver staining and XGAL staining in the 
same sections. Thus, by using these different approaches 
(immunofluorescent vs. histochemical staining), Applicant is 
able to determine if Pnmt+ cells become cardiac neurons. The 
US 8,614,091 B2 
35 
development, function, and regulation of the intrinsic cardiac 
nervous system are not well understood. Consequently, this 
experiment could shed new light on this relatively unexplored 
aspect of cardiac development. 
The experiments with the aged hearts is performed prima-
rily to see ifthere is any loss or attrition of Pnmt+ cell descen-
dents in the heart over time. These experiments are performed 
on a limited basis unless major differences are noted between 
aged, adult, and neonatal patterns of Lacz expression in the 
hearts of these mice. 
Based on the published and preliminary data, Pnmt+ cells 
may primarily give rise to cardiomyocytes. Applicant antici-
pates that some of these cells may contribute to neural crest 
derivatives in the heart since the preliminary data suggest that 
Lacz+ neural crest cells may invade the heart in Pnmt-
CrexR26R embryos. Moreover, the Pnmt+ cells that eventu-
ally populate the adrenal medulla are known to be derived 
from migrating neural crest cells. Thus, there is precedence 
for a neural crest origin of Pnmt+ cells in other tissues, and it 
is certainly possible that this is also true in the heart. Thus, 
Applicant carefully examines Lacz expression in these hearts 
to see ifit is consistent with known patterns of neural crest cell 
distributions in the heart (e.g., outflow tract septum). Since 
cardiac neurons are also thought to arise from neural crest, 
Applicant may expect to see some co-staining for Lacz and 
neuronal markers such as ChAT. 
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into the endogenous Pnmt gene locus as well as the potential 
usefulness of the nEGFP reporter as a viable marker for 
Pnmt+ cells. Since Applicant has already demonstrated that 
another Pnmt knock-in gene, Pnmt-Cre, was expressed spe-
cifically as expected in vivo, Applicant expects that nEGFP 
expression displays a similar pattern of specificity, especially 
with respect to the ICA cells in the developing heart and the 
chromaffin cells in the adrenal medulla. Pnmt is normally 
expressed in limited numbers of cells in various other tissues 
10 including brainstem and retinal neurons, lung, spleen, thy-
mus, and testes. 
In certain cases, Applicant is able to use the recombinant 
Pnmt-nEGFP ES cells to generate cardiomyocyte progenitor 
cells by inducing them to differentiate into beating cardiac 
15 cells in vitro. For the purpose of this project, generation of 
Pnmt-nEGFP mice is not necessary, but would certainly help 
provide confidence in the fidelity of this targeted reporter 
gene. In addition, the mice could provide an alternative 
source of cardiomyocyte stem (Pnmt+) cells (e.g., instead of 
20 cardiac-differentiated recombinant ES cells) for the trans-
plantation experiments described for the latter aims. One 
attractive alternative to Pnmt-nEGFP expression as a reporter 
would be expression of a unique cell surface marker gene 
from the Pnmt locus. Applicant could then use fluorescently-
25 tagged antibody strategies to identify the cells and mark them 
for isolation using FACS. There are many potential marker 
genes that could be tested as such. Another experiment is to identify Pnmt+ cells in the heart 
using Pnmt-nEGFP knock-in mice. To develop a "tag" for 
living Pnmt+ cells in mice, Applicant has created a new line of 
Pnmt knock-in mice that express a nuclear-localized 
Enhanced Green Fluorescent Protein (nEGFP) reporter gene 
from the endogenous Pnmt gene locus. Applicant hypoth-
esizes that Pnmt+ cells express nEGFP in these mice, and 
Applicant tests this hypothesis by analyzing fixed tissue sec-
tions for nEGFP expression using confocal laser-scanning 35 
fluorescence microscopy. The specificity of nEGFP expres-
sion in this newly developed model is validated. 
Another aim is to isolate and characterize living cardiac 
Pnmt+ cells in vitro using fluorescence-activated cell sorting 
30 (FACS) and magnetic microsphere particle loading tech-
niques. This aim focuses on optimizing methods for isolating 
Pnmt+ cells and loading them with magnetic microsphere 
particles for subsequent transplantation and in vivo imaging 
analyses. 
One experiment is to isolate Pnmt+ cells from cardiac-
differentiated Pnmt-nEGFP recombinant ES cells. Applicant 
plans to take advantage of nEGFP expression from the endog-
enous Pnmt gene locus to identify and isolate presumptive 
cardiomyocyte progenitor (Pnmt+) cells from other types of 
Applicant validates the new Pnmt-nEGFP knock-in model 
by first showing that insertion of the nEGFP reporter effec-
tively disrupted the expression of the endogenous Pnmt gene. 
Two independent assays are performed to accomplish this 
goal. First, Applicant measures epinephrine and norepineph-
rine concentrations in the adrenal glands, heart, and blood 
from wild-type (Pnmt+1"'), heterozygous (Pnmt+lnEGFP) and 
homozygous reporter (PnmtnEGFP!nEGFP) mice using a stan-
dard radioimmunoassay, as Applicant has described previ-
ously (Ebert & Thompson, 2001, supra]. Second, Applicant 
compares nEGFP expression in various tissues (adrenal 
glands, heart, etc.) with endogenous Pnmt expression using 
immunofluorescent histochemical staining methods. 
To confirm and extend the findings from the experiments 
with Pnmt-CrexR26R mice, Applicant examines co-expres-
sion of nEGFP with the various cell type-specific antigens 
listed in Table 5, by using immunofluorescent histochemical 
staining. nEGFP expression is identified by direct fluores-
cence emission (green) from the nEGFP reporter protein 
while co-staining is performed with immunofluorescent his-
tochemical techniques using red fluorescent (Texas Red or 
TRITC) secondary antibodies. 
40 cardiac precursor cells using FACS. This strategy may pro-
vide a means to selectively obtain a novel population of 
cardiomyocyte stem cells that are evaluated in the transplan-
tation experiments described above. 
Applicant initiates cardiac differentiation in Pnmt-nEGFP 
45 ES cells using the "hanging ball" method. The process takes 
7 days to form embryoid bodies that are then transferred to 
tissue cultureware for attachment. Beating activity develops 
in the focal adhesion plane over the next few days (e.g., 7+1, 
7+2, 7+3 days). Neither the endogenous Pnmt gene nor the 
50 Pnmt-nEGFP gene was expressed in undifferentiated ES 
cells, but both were activated during cardiac differentiation. 
Endogenous Pnmt mRNA was readily detected at 7+1 and 
7+3 days, in strong concurrence with the abundant appear-
ance of nEGFP+ cells at these stages in cardiac-differentiated 
55 Pnmt-nEGFP ES cells. These cardiac-differentiated ES cells 
can be dispersed into single cells using published methods 
that Applicant has successfully employed. The next step, 
therefore, is to isolate these cells from non-EGFP+ cells using 
FACS. 
Applicant expects to find that nEGFP expression is 60 
restricted to Pnmt+ cells in vivo, and that homozygous knock-
Applicant expects to selectively recover EGFP+ cells from 
a dispersed population of semi-differentiated ES cells. 
Although Applicant may ultimately need fewer or more cells 
for the transplantation experiments, Applicant uses this range 
(XX-YY) as an initial benchmark for the number of EGFP+ 
cells needed for each transplantation experiment. Because 
mouse ES cells can be readily expanded and differentiated in 
culture, it is not unrealistic to achieve yields in this range. 
in reporter (Pnm~EGFP!nEGFP) mice do not express endog-
enous Pnmt or produce epinephrine. In contrast, wild-type 
(Pnmt+1+) and heterozygous (Pnmt+lnEGF~ mice are 
expected to express Pnmt and produce normal levels of epi- 65 
nephrine (as was true for Pnmt-Cre mice). Such results would 
help to confirm the specificity ofthetargetednEGFP insertion 
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Indeed, Zandstra et al. [2003] recently demonstrated "Scal-
able production of ES cell-derived cardiomyocytes" using a 
similar FACS-based strategy. Thus, it appears feasible to 
obtain sufficient numbers of cells using this strategy. 
Another experiment is to isolate Pnmt+ cells from embry-
onic mouse hearts (Pnmt-nEGFP mice). A potential limita-
tion of ES cells is that they may differentiate into non-cardiac 
as well as cardiac cells. Applicant aims to overcome this 
limitation by selecting Pnmt-nEGFP+ cells from cardiac-dif-
ferentiated ES cells, but Applicant cannot be certain that all 
nEGFP+ cells isolated in this manner are cardiac-destined. 
Indeed, Pnmt is also expressed in neurons, chromaffin cells, 
and other types of cells that could conceivably "contaminate" 
the ES cell preparations. To minimize this concern, Applicant 
also isolates Pnmt-nEGFP+ cells from embryonic/fetal 
mouse hearts for use in the subsequent transplantation experi-
ments described above. 
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cardiac or pre-cardiac stem cells. Conversely, Applicant also 
expects that some nEGFP- cells do not differentiate into 
nEGFP+ cells because they have already proceeded through 
the cardiomyocyte stem (CMS) cell stage of development or 
because they have differentiated along a different pathway or 
not at all. This analysis, while tedious, can be a very powerful 
tool for determining differentiation potentials of individual 
cells discriminated by their ability to express nEGFP from the 
Pnmt gene locus. 
10 Another experiment is to perform magnetic particle-load-
ing of Pnmt-nEGFP+ cells in vitro. To track the position of 
transplanted cells in vivo using MRI, Applicant pre-loads 
them with magnetic particles in vitro. Demonstration that 
15 
Applicant can specifically isolate nEGFP+ cells pre-loaded 
with magnetic particle beads would set the stage for the 
transplantation and molecular imaging experiments. 
Applicant induces cardiac differentiation in recombinant 
Pnmt-nEGFP ES cells. After the embryoid bodies are placed 
20 onto culture plates (day 7), they are overlaid with polymer-
coatedmagnetic micro sphere particles for 24-48 hours. At the 
end of this incubation period, Applicant removes the media 
and disperse the cells for FACS isolation. The FACS isolation 
method can be modified to allow selective isolation of cells 
Applicant uses essentially the same strategy as described 
for the previous experiment except that Applicant's source 
material includes embryonic and fetal hearts from transgenic 
Pnmt-nEGFP knock-in mice. Applicant expects that Pnmt-
nEGFP+ cells isolated from embryonic/fetal hearts and car-
diac-differentiated ES cells behave similarly in subsequent 
differentiation and transplantation experiments. By compar-
ing Pnmt-nEGFP+ cells obtained from these two different but 25 
related sources, Applicant is able to determine if there are 
significant differences in the differentiation/transplantation 
potential of these cell populations. 
that have green fluorescent nuclei (due to nEGFP expression 
from the Pnmt locus) and red fluorescent cytoplasm (due to 
the presence of Dragon Red polymer-coated magnetic micro-
sphere particles). A subset of these cells is fixed onto cover-
slips for photo-documentation of particle loading using dual Another experiment is to perform clonal analysis of Pnmt-
nEGFP+ cells. To characterize the differentiation potential of 30 
Pnmt-nEGFP+ cells isolated from cardiac-differentiated ES 
fluorescence microscopy. 
Since these magnetic micro sphere particles have been suc-
cessfully used to pre-load mouse ES cells as well as several 
other types of cells in culture, Applicant expects that they also 
effectively pre-load Pnmt-nEGFP+ cells. An obvious poten-
cells and embryonic/fetal hearts, Applicant analyzes clonal 
colonies of nEGFP+ and non-fluorescent kindred cells 
obtained during preparation of the cells. Applicant hypoth-
esizes that nEGFP cells differentiate into cardiomyocytes and 
cease to express nEGFP. By immunofluorescent cytochemi-
cal staining of clonal populations with cell type-specific anti-
body markers (Table 5), the fate ofEGFP+ vs. EGFP cells can 
be determined. This analysis may also provide a means to 
optimize culture conditions for production of cardiomyocyte 
stem cells for subsequent transplantation and molecular 
imaging experiments. 
Applicant disperses cardiac-differentiated recombinant 
Pnmt-nEGFP ES cells and embryonic/fetal mouse hearts car-
rying the Pnmt-nEGFP knock-in transgene into single-cell 
suspensions, and culture them at a density of .1 toreq.1 cell per 
well in a 48-well culture dish containing a round glass cov-
erslip. The coverslips be coated with different types of extra-
cellular matrix materials (laminin, collagen, fibronectin, 
matrigel, etc.) to determine if any of these treatments influ-
ences the differentiation and growth potential of the seeded 
cells. Immediately after seeding, each well is examined and 
scored forthe presence or absence of an EGFP+ or EGFP- cell 
35 tial difficulty is that Pnmt-nEGFP+ cells may not take up the 
particles efficiently or that Applicant is unable to isolate suf-
ficient numbers of particle-loaded cells to effectively evaluate 
MRI tracking of these cells once transplanted. It is apparent, 
however, that if the cells are loaded with the particles, then 
40 they are relatively easy to track by MRI. Nevertheless, if 
Applicant has difficulty loading these cells using the strategy 
outlined above, Applicant isolates the nEGFP+ cells by FACS 
first, and then load them with the particles. This would have 
the advantage of enriching the population of cells to be loaded 
45 with the desired type of cells (Pnmt-nEGFP+) for the subse-
quent transplantation and molecular imaging experiments. 
Another alternative strategy would be to load the cells with 
different types of magnetic particles. Optionally, Applicant 
may simply load cardiac-differentiated cells en masse. Cells 
50 pre-loaded with magnetic particles are separated from free 
particles using Percoll gradients, as previously described. 
Another aim is to identify and track cardiac Pnmt+ cells in 
vivo using magnetic resonance imaging (MRI) techniques 
following transplantation of these cells into regions of the 
55 mouse heart damaged by myocardial infarction (MI) or 
cryoablation. This aim determines if Pnmt+ cells persist in the 
heart following transplantation into damaged hearts and if so, 
whether or not cardiac performance is improved as a result of 
this intervention. 
by careful (manual) inspection using fluorescence micros-
copy. Each well is similarly examined on a near-daily basis 
for 2-3 weeks. Any signs of myocardial development (stria-
tions, contractions, etc.) are duly noted. At the end of this 
visual inspection period, Applicant fixes the cells on the cov-
erslips and subject them to immunofluorescent cytochemical 
staining using cell type-specific antibodies (Table 5) to deter- 60 
mine which cardiac cell types, if any, emerge from this clonal 
expansion in culture. 
One experiment is to tracking transplanted cardiomyocyte 
stem cells using MRI. Applicant hypothesizes that cardi-
omyocyte stem cells transplanted into damaged regions of the 
heart facilitate repair and regeneration of the damaged cardiac 
tissue. Thus, the transplanted cells may remain near the site of 
Applicant anticipates that at any given stage of cardiac 
development, there is a heterogeneous mixture of heart-like 
cells representing many different stages of development and 
differentiation. Thus, Applicant expects that some nEGFP-
cells may become nEGFP+ if they represent an early stage of 
65 transplantation and ultimately contribute to new myocyte 
formation in the damaged regions. This, in turn, should lead to 
improved cardiac performance. As a first step towards testing 
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this hypothesis, Applicant identifies and track the location of 
the transplanted cardiomyocyte stem cells in vivo using MRI. 
Cardiomyocyte stem cells (Pnmt-nEGFP+ or similar cells) 
are pre-loaded and isolated as described above. These cells 
are delivered to a region of the heart damaged by experimen-
tally-induced myocardial infarction (MI). For controls, 
Applicant performs mock transplantations and transplanta-
tion of non-selected cardiac-differentiated ES cells pre-
loaded with magnetic microsphere particles. Applicant per-
forms the transplantations at various times post-MI to 10 
determine if there is an optimal window of opportunity for 
this type of cell-based intervention. In addition, Applicant 
also varies the number of cells used per transplantation to 
determine what the optimal number of these cells is for this 
purpose. In each case, the transplanted cells are identified and 15 
tracked in vivo over a period of at least several days, and 
possibly weeks or months ifthe cells/signal persists. The MRI 
results may show that the transplanted cardiomyocyte stem 
cells remain in the heart at or near the region damaged by the 
infarction. 20 
40 
of these cells (indicating that Pnmt-nEGFP expression had 
been shut down during differentiation of the transplanted 
CMS cells in vivo). Further, if the transplanted cells have 
differentiated into myocytes, then Applicant expects that cells 
containing the fluorescent magnetic particles express myo-
cyte-specific markers such as sarcomeric a-actinin. Finally, 
Applicant expects to see significant thickening of muscle 
tissue in the infarcted region of hearts receiving transplanted 
CMS cells relative to control hearts that did not receive trans-
plants. 
Another aim is to assess the myocyte differentiation poten-
tial of Pnmt+ cells in vivo using bioluminescence imaging 
(BLI) techniques following transplantation of transgenic 
myocyte-specific promoter-luciferase reporter cells into 
regions of the mouse heart damaged by MI or cryoablation. 
This aim determines if transplanted Pnmt+ cells differentiate 
into specific types of myocytes in vivo by evaluating 
luciferase reporter gene expression over time using BLI tech-
niques. 
One experiment is to perform bioluminescent imaging of 
transplanted recombinant ES luciferase reporter cells. The 
rationale is that if transplanted cardiomyocyte stem cells dif-
ferentiate into myocytes in vivo, then they should begin to 
robustly express myocyte-specific genes. This expression can 
potentially be monitored in vivo using BLI to identify and 
quantify luciferase reporter expression driven from a strong 
well-characterized myocyte-specific promoter. Applicant 
uses the cardiac a-myosin heavy chain ( aMHC) promoter 
fused to a luciferase reporter gene to create a new recombi-
One alternative strategy that could prove beneficial here is 
the use of more localized cryoablation damage rather than MI 
damage, which can affect a relatively larger portion of the 
heart. There may be some advantage in trying to repair/re-
generate a smaller region of damage. An additional advantage 25 
of cryoablation is that Applicant may be able to target more 
specific areas such as pacemaker myocytes in the SA node. 
Since Applicant has shown that Pnmt+ cells developmentally 
contribute to pacemaker myocytes, this would be an attractive 
model to analyze for this project. 30 nant ES cell line derived from recombinant Pnmt-nEGFP ES 
Another experiment is to perform functional assessments 
of cardiac performance in damaged hearts following trans-
plantation of cardiomyocyte stem cells into the damaged 
regions in vivo. Applicant hypothesizes that cardiac perfor-
mance is improved following transplantation of cardiomyo- 35 
cyte stem cells into damaged regions of the heart. Applicant 
primarily uses MRI to perform these assessments, which can 
be done in parallel with the MRI tracking experiment 
described above. Heart rate/rhythmicity and left ventricular 
ejection fraction is measured as the endpoints for this experi- 40 
ment. Applicant compares cardiac performance in MI mice 
that received cardiomyocyte stem cell transplants vs. those 
that did not (mock transplants). Normal (non-MI) littermates 
serve as an additional control group. 
Another experiment is to perform postmortem histological 45 
assessment of damaged/repaired cardiac regions. If repair of 
damaged tissue occurs as a result of cardiomyocyte stem cell 
transplantations, then Applicant expects to see some evidence 
of regeneration by examining the damaged region using his-
tological methods. At the termination of the MRI tracking 50 
experiment, the mouse is humanely sacrificed and the heart is 
fixed, processed, and sectioned for histological assessment. 
To determine the location of the transplanted cells and their 
descendents (if present), Applicant looks for cells harboring 
the fluorescent magnetic particles (Dragon Red) that were 55 
loaded into the cells prior to transplantation. These assess-
ments are combined with immunofluorescent histochemical 
staining techniques using cell type-specific antibodies (Table 
5) to determine if the transplanted cells differentiated into 
myocytes or some other type of cardiac cell. In addition, 60 
Applicant measures the size of the infarcted region from 
control and transplanted hearts using morphometric methods. 
Applicant expects that the transplanted cells remain in the 
heart where they predominantly become myocytes. Thus, 
Applicant expects to find cells that have red fluorescent beads 65 
in the cytoplasm (marking transplanted cells and their prog-
eny), with little or no green fluorescence retained in the nuclei 
cells. Applicant then tests the resulting stably transfected 
clones for their ability to express luciferase in undifferenti-
ated vs. cardiac-differentiated ES cells. 
Applicant expects that luciferase expression is low or 
absent in undifferentiated ES cells, but is strongly activated 
and sustained once the cells differentiate into myocytes. 
Since Applicant has previously shown that there is an inverse 
relationship between cardiac Pnmt expression and myocyte-
specific expression (Ebert & Thompson, 2001, supra), Appli-
cant also predicts that Pnmt-nEGFP+ cells are not substan-
tially express luciferase, at least until Pnmt promoter activity 
(and the resulting nEGFP expression) begin to shut down as 
myocyte differentiation proceeds. Thus, upon transplantation 
of these recombinant (Pnmt-nEGFP/960 MHC-Luc) ES cells 
into infarcted or ablated regions of the mouse heart, Applicant 
expects Pnmt-nEGFP expression to decline and aMHC-Luc 
to increase as an indicator of myocyte differentiation in vivo. 
One alternative would be to transplant ES cells that had 
already differentiated into myocytes, and hence, would 
already be expressing high levels of aMHC-Luc. The main 
difference between this strategy and the primary strategy is 
that Applicant would not pre-select Pnmt-nEGFP cells by 
FACS prior to transplantation. In other words, the ES cells are 
differentiated into beating cardiac cells, dispersed, collected 
and transplanted en masse into damaged hearts. This should 
provide a "maximum" luciferase signal from these cells for 
BLI. If this alternative strategy now permits detection of 
luciferase activity from the heart in vivo using BLI, then this 
would suggest that Applicant is primarily dealing with an 
issue of BLI sensitivity. Applicant also considers using a 
different myocyte-specific promoter such as cardiac actin or 
sarcomeric a-actinin. 
Another alternative would be to sacrifice the animals at 
various times post-transplantation, and assay cardiac protein 
extracts for luciferase activity. Such method would be a pow-
erful and straightforward method for determining if there was 
any increase in luciferase expression following transplanta-
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tion. If Applicant observes significant increases in aMHC-
Luc activity in these extracts over time, then this would also 
point to a sensitivity issue for the BLI measurements. If, on 
the other hand, little or no luciferase activity is produced from 
transplanted heart extracts, then this would indicate that the 
transplanted cells are probably not differentiating into myo-
cytes. In either case, these results are supported by the histo-
logical assessments described in the previous experiment. 
42 
Consistent with this idea, acute treatment of spontaneously 
beating myocyte cultures with either the al-selective antago-
nist, prazosin, or the ~-selective antagonist, timolol, led to 
dose-dependent decreases in the beating rate within seconds 
after drug application (FIG. 16). Significant slowing (-25% 
decrease) in the beating rate was observed in the presence of 
1 µM prazosin (p<0.01, n=l 0). When the prazosin concentra-
tion was increased to 10 µM, severe depression (>85% 
decrease) in the beating rate occurred. Timolol also caused 
Example 4 
Intrinsic Cardiac Catecholamines Help Maintain Beating 
Activity in Neonatal Rat Cardiomyocyte Cultures 
10 significant concentration-dependent slowing in the beating 
rate (p<0.01, n=6). These results show that application of 
either al- or ~-adrenergic receptor blockers lead to concen-
tration-dependent slowing of beating rate. 
To test the possibility that serum catecholamines may have 
1. Results 
15 influenced our results, Applicant stripped the serum using 
charcoal-treatment to remove any trace amounts of catechola-
mines that may have been present. Beating activity was main-
tained for at least 72 h after charcoal-stripping (FIG. 17). The 
~-blocker timolol strongly suppressed beating activity under 
To identify ICA cells in neonatal rat hearts, Applicant used 
immunofluorescent histochemical staining techniques using 
antibodies that specifically recognize the major catechola-
mine biosynthetic enzymes. Many brightly labeled fluores-
cent cells were identified using anti-PNMT antiserum. Co-
staining with an anti-TH antibody revealed an essentially 
identical pattern of expression. These ICA cells were prima-
rily found in the ventricular myocardium near the endocardial 
surface, but were also observed sporadically throughout the 
heart. A similar pattern of co-staining was observed when 
Applicant used anti-DBH and anti-TH antibodies. Positively 
labeled cells appeared bright, were roundish or triangular in 
shape, and primarily displayed cytoplasmic staining patterns. 
Thus, each of the three independent catecholamine biosyn-
thetic enzyme (TH, DBH, and PNMT) antibodies selectively 30 
labeled a highly similar subset of cardiac cells in neonatal rat 
hearts. 
20 these conditions, an effect that was fully rescued by the addi-
tion of epinephrine (FIG. 17). Similarly, application of the 
al-blocker prazosin led to significant decreases in beating 
rates (FIG. 18). The addition of the al-selective agonist, 
L-phenylephrine, resulted in a dose-dependent reversal of the 
25 prazosin-induced decrease in beating rate. These results show 
that al- and ~-adrenergic receptor antagonists were effective 
at blocking beating even in the absence of any potential influ-
ence from serum catecholamines. 
2. Materials and Methods 
A) Materials. All drugs and chemicals used for this study 
were purchased from Sigma Chemical (St. Louis, Mo., 
U.S.A.). Drugs were prepared as concentrated stock solutions 
and frozen in small aliquots at -SO.degree. C. The stock 
aliquots were thawed immediately before use and were not 
35 refrozen. Rabbit anti-PNMT and anti-DBH antisera have 
To view these presumptive ICA cells in relation to cardi-
omyocytes, Applicant co-stained sections for PNMT and a 
myocyte-specific marker, sarcomeric a-actinin. Individual 
ICA cells were again identified in ventricular myocardium. 
When co-stained for a-actinin, a characteristic ladder-like 
sarcomeric pattern was evident in many myocytes. By super-
imposing the PNMT and a-actinin images, Applicant 
obtained an "overlay" image where ICA cells can be visual- 40 
ized in direct juxtaposition to underlying myocytes. To iden-
tify ICA cells in primary cultures of neonatal rat cardiomyo-
cytes, Applicant seeded the cardiomyocytes onto collagen-
coated coverslips and allowed them to develop into 
synchronous rhythmic beating clusters of cardiomyocytes 45 
over a 7-d period. The cells were then fixed and co-immun-
ofluorescently labeled for PNMT and sarcomeric a-actinin. 
PNMT staining was punctate and cytoplasmic, whereas a-ac-
tinin staining was evident in sarcomeric structures. The over-
lay image shows an ICA cell sitting atop a cluster of cardi- 50 
omyocytes. ICA cells could also be identified in these 
cultures by co-staining for DBH and TH. Although the rela-
tive abundance ofICA cells in these neonatal rat cardiomyo-
cyte cultures was low (only -1 ICA cell/2xl05 myocytes), 
these results nevertheless show that ICA cells were present 55 
and that they were closely associated with cardiomyocyte 
clusters. 
To determine whether beating activity in culture was 
dependent upon local catecholamine production, the wells 
were treated with increasing concentrations of reserpine, a 60 
catecholamine-depleting agent. Significant dose-dependent 
decreases in beating rates were observed in the presence of 
reserpine (FIGS. 15A and B). These decreases could be 
largely reversed by the addition of norepinephrine (FIG. 
15C). These results suggest that endogenous catecholamines 65 
are needed for the maintenance of beating rates in these 
cardiomyocyte cultures. 
been previously described (3). Mouse monoclonal anti-TH 
and anti-sarcomeric a-actinin antibodies were purchased 
from Sigma Chemical. FITC-conjugated donkey anti-rabbit 
and TRITC-conjugated donkey anti-mouse secondary anti-
bodies were obtained from Jackson Immunoresearch (West 
Grove, Pa., U.S.A.). 
B) Animals. Timed-pregnant Sprague-Dawley rats were 
obtained from Taconic Farms (Germantown, N.Y., U.S.A.). 
Neonatal pups were used within the first 2 d after birth. All 
experiments were conducted in strict concordance with the 
guidelines provided by the Georgetown University Animal 
Care and Use Committee and the National Institutes of 
Health. 
C) Immunofluorescent histochemical and cytochemical 
staining. Double immunofluorescent staining of neonatal rat 
hearts and cardiomyocyte cultures was performed essentially 
as described previously (3). For immunofluorescent 
cytochemical staining of cultured cardiomyocytes, the myo-
cytes were seeded onto collagen-coated coverslips (12 mm 
round) at the time of isolation, and allowed to grow in culture 
for 7-9 d before fixation. To fix the cells, the culture medium 
was removed and the cells were rinsed twice with PBS. The 
cells were then exposed to 4% paraformaldehyde in PBS for 
15 min at room temperature. At the end of this fixation period, 
the fixative was removed and the cells were washed twice 
with PBS. The cells were then used immediately for immu-
nofluorescent staining or stored in PBS in 4.degree. C. for 
subsequent staining. 
Because the anti-DBH and anti-PNMT antisera were pro-
duced in rabbits while the anti-TH antibody was produced in 
mice, FITC-conjugated anti-rabbit (green fluorescence) and 
TRITC-conjugated anti-mouse (red fluorescence) secondary 
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antibodies were used to detect specific labeling ofDBH- (or 
PNMT-) and TH-expressing cells, respectively. Applicant has 
previously demonstrated the specificity of these antibodies 
using immunofluorescent histochemical staining assays. 
D) Preparation of rat neonatal cardiomyocyte cultures. 
44 
was enclosed in a temperature-controlled (37.degree. C.), 
custom-designed incubation chamber (Part numbers: 8400-
00S, 8S06-0SO, and 8S37-02S; Coy Laboratory Products, 
Inc., Grass Lake, Mich., U.S.A.) fed with S% C0i9S% air to 
maintain constant pH. The photodiode sensor signal was fil-
tered with an 8-pole Bessel low-pass filter (Model 900CT, 
Frequency Devices, Inc., Havervill, Mass., U.S.A.) with a 
cutoff frequency of 1000 Hz, and relayed to a PC equipped 
with a National Instruments data acquisition board and Lab-
10 View 4.0 processing software. Parallel outputs were also 
directed to a Gould TASSO chart recorder and an oscilloscope. 
Data were continuously acquired and stored to disk for later 
analysis. Drugs were added and immediately mixed in the 
media overlying the cells in each well. Predrug (baseline) 
Neonatal rat cardiomyocytes were prepared according to 
Simpson and Savion, 1982, Circ Res SO: 101-116, with the 
following modifications: Neonatal rat pups were killed by 
swift decapitation within the first 2 dafter birth. The heart was 
immediately removed under aseptic conditions and placed in 
ice-cold sterile HBSS (no ca++ or Mg++). Enzymatic and 
mechanical dissociation of cardiomyocytes was then per-
formed using the Neonatal Cardiomyocyte Isolation System 
supplied by Worthington Biochemicals (Freehold, N.J., 
U.S.A.). The hearts were minced on ice and digested over-
night at 4.degree. C. with purified trypsin (10 µg/mL) in 
HBSS. On the following morning, the digested tissue was 
transferred to a SO-mL conical tube and purified soybean 
trypsin inhibitor (40 µg/mL) was added to terminate 
trypsinization. The tissue was oxygenated and warmed to 
37.degree. C. Purified collagenase (10 U/mL) was added and 
digestion proceeded for 4S min at 37.degree. C. with inter-
mittent gentle swirling. Mild trituration was then used to 
mechanically dissociate the digested tissue, and single-cell 
suspensions were obtained by filtering this digested material 
through 70 µm sterile mesh filters. The cells were collected by 
low-speed centrifugation. The supernatant was discarded and 
the cell pellet resuspended in DMEM (high glucose, Bioflu-
ids, Rockville, Md., U.S.A.) culture medium containing 10% 
defined iron-supplemented bovine calf serum (Hyclone 
Laboratories, Logan, Utah, U.S.A.), 2 mM glutamine, and 
gentamicin sulfate (SO µg/mL). In some experiments, the 
serum was pretreated with charcoal before adding it to the 
media (10% volume as above) to remove possible trace 
35 
amounts of catecholamines that may have been present The 
cells were then "preplated" to remove fibroblasts, and the 
remaining cells counted and seeded onto multi-well culture 
plates at a density of7S,OOO cells per cm2 . The media was 
changed every 2-3 d beginning the day after seeding. Bro-
40 
modeoxyuridine (0 .1 mM) was added to the culture media for 
the first 3 d to further minimize contamination from fibro-
blasts. 
E) Beating rate measurements. Beating activity of cultured 
cardiomyocytes was measured by edge-detection using pho-
todiode sensors attached to a monitor screen depicting beat-
ing cells viewed by videomicroscopy. The entire microscope 
<160> NUMBER OF SEQ ID NOS, 3 
<210> SEQ ID NO 1 
<211> LENGTH, 24 
<212> TYPE, DNA 
SEQUENCE LISTING 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
15 
measurements were performed first, and the indicated drug(s) 
were added as a 1 OOx stock to the preexisting media on each 
well, and rapidly mixed. Beating rates were remeasured 
within 2-3 min after drug addition. 
F) Data analysis. The number of beating rate measure-
20 ments was typically obtained from different wells of multi-
well plates (usually six wells per plate), seeded from the same 
preparation of myocytes. Measurements were obtained 
immediately before and after the addition of specified drugs. 
In the reserpine experiment, beating rate measurements were 
25 
obtained at multiple time-points after drug administration. 
Each experiment was replicated at least twice using indepen-
dently isolated cultures, and a representative result from each 
is shown. Unless otherwise indicated, all beating rate mea-
surements were performed on cells that had been cultured for 
30 
7-9 d. All data are expressed as mean.+-.SEM. Statistical 
significance was assessed by one-way ANOVA, with p<O.OS 
required to reject the null hypothesis. Posthoc testing was 
performed using Bonferroni's correction for multiple com-
parisons. 
Incorporation by Reference 
All publications and patents mentioned herein are hereby 
incorporated by reference in their entirety as if each indi-
vidual publication or patent was specifically and individually 
indicated to be incorporated by reference. 
While specific embodiments of the subject invention have 
been discussed, the above specification is illustrative and not 
restrictive. Many variations of the invention will become 
apparent to those skilled in the art upon review of this speci-
fication and the claims below. The full scope of the invention 
45 
should be determined by reference to the claims, along with 
their full scope of equivalents, and the specification, along 
with such variations. 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 1 
caggcgcctc atccctcagc agcc 
<210> SEQ ID NO 2 
<211> LENGTH, 24 
<212> TYPE, DNA 
24 
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-continued 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 2 
ctggccagcg tcggagtcag ggtc 
<210> SEQ ID NO 3 
<211> LENGTH, 32 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
24 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 3 
ggtgtacggt cagtaaattg gacaccgtcc tc 
The invention claimed is: 
1. An isolated Phenylethanolamine N-methyltransferase 
(Pnmt)-positive cardiac progenitor cell, wherein the cardiac 
progenitor cell is committed to at least one cardiomyocyte 
specific lineage selected from the group consisting of a pace-
maker cell, a His bundle (HIS) cell, a Purkinje fiber (PUR) 
cell, an atrial working myocyte, and a ventricular working 
myocyte. 
2. The isolated progenitor cell of claim 1, wherein the 
progenitor cell is positive for a marker selected from the 
group consisting of c-kit, Sca-1,and MDRl. 
32 
3. The isolated progenitor cell of claim 1, wherein the 
cardiomyoctye is a pacemaker cell selected from the group 
consisting of a sinoatrial node (SAN) cell and an atrioven-
25 tricular node (AYN) cell. 
4. The isolated progenitor cell of claim 1, wherein the 
progenitor cell is isolated from a tissue selected from the 
group consisting of a developing heart and an adult heart. 
30 
5. The isolated progenitor cell of claim 1, wherein the 
progenitor cell is isolated from a cultured stem cell line. 
* * * * * 
